


We claim:

1. A compound of the formula I,



wherein


- 5  $R^0$  is 1) a monocyclic or bicyclic 6- to 14-membered aryl, wherein aryl is mono-, di- or trisubstituted independently of one another by R8,
- 2) a monocyclic or bicyclic 4- to 15-membered heterocyclyl selected from the group consisting of benzimidazolyl, 1,3-benzodioxolyl, benzofuranyl, benzoxazolyl, benzothiazolyl, benzothiophenyl, cinnolinyl, chromanyl, indazolyl, indolyl, isochromanyl, isoindolyl,
- 10 isoquinolinyl, phenylpyridyl, phthalazinyl, pteridiny, purinyl, pyridyl, pyridoimidazolyl, pyridopyridinyl, pyridopyrimidinyl, pyrimidinyl, quinazolinyl, quinolyl, quinoxalinyl and 1,4,5,6-tetrahydro-pyridazinyl, wherein said heterocyclyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R8, or
- 3) a monocyclic or bicyclic 4- to 15-membered heterocyclyl, containing one, two, three
- 15 or four heteroatoms chosen from nitrogen, sulfur or oxygen, wherein said heterocyclyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R8, and is additionally substituted by a monocyclic or bicyclic 4- to 15-membered heterocyclyl, containing one, two, three or four heteroatoms chosen from nitrogen, sulfur or oxygen, wherein the heterocyclyl is unsubstituted or mono-, di- or trisubstituted independently of one
- 20 another by R8;

- R8 is 1) halogen,
- 2)  $-\text{NO}_2$ ,
- 3)  $-\text{CN}$ ,
- 25 4)  $-\text{C}(\text{O})-\text{NH}_2$ ,
- 5)  $-\text{OH}$ ,
- 6)  $-\text{NH}_2$ ,
- 7)  $-\text{O}-\text{CF}_3$ ,
- 8) a monocyclic or bicyclic 6- to 14-membered aryl, wherein the aryl is mono-, di- or
- 30 trisubstituted independently of one another by halogen or  $-\text{O}-(\text{C}_1-\text{C}_8)\text{-alkyl}$ ,

- 9)  $-(C_1-C_8)$ -alkyl, wherein the alkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by halogen,  $NH_2$ ,  $-OH$  or methoxy,
- 10)  $-O-(C_1-C_8)$ -alkyl, wherein the alkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by halogen,  $NH_2$ ,  $-OH$  or methoxy,
- 5 11)  $-SO_2-CH_3$  or
- 12)  $-SO_2-CF_3$ ,

provided that when  $R^0$  is a monocyclic or bicyclic 6- to 14-membered aryl, then  $R^8$  is least one of the substituent of the aryl is halogen,  $-C(O)-NH_2$  or  $-O-(C_1-C_8)$ -alkyl;

10 the substructure



in formula I is a 4-to 8 membered saturated, partially unsaturated or aromatic cyclic group containing zero, 1, 2, 3 or 4 heteroatoms chosen from nitrogen, sulfur or oxygen and is unsubstituted or substituted 1, 2, 3, 4, 5 or 6 times by  $R^3$ , or substituted 1 or 2 times by  $=O$ ,

15 provided that said cyclic group is not a phenyl residue;

Q is a direct bond,  $-(C_0-C_2)$ -alkylene- $C(O)-NR^{10}$ -,  $-NR^{10}-C(O)-NR^{10}$ -,  $-NR^{10}-C(O)-$ ,  $-SO_2$ -,  $-(C_1-C_6)$ -alkylene,  $-(CH_2)_m-NR^{10}-C(O)-NR^{10}-(CH_2)_n$ -,  $-(CH_2)_m-NR^{10}-C(O)-(CH_2)_n$ -,  $-(CH_2)_m-S-(CH_2)_n$ -,  $-(CH_2)_m-C(O)-(CH_2)_n$ -,  $-(CH_2)_m-SO_2-NR^{10}-(CH_2)_n$ -,  $-(CH_2)_m-NR^{10}-SO_2-(CH_2)_n$ -,  $-(CH_2)_m-NR^{10}-SO_2-NR^{10}-(CH_2)_n$ -,  $-(CH_2)_m-CH(OH)-(CH_2)_n$ -,  $-(CH_2)_m-O-C(O)-NR^{10}-(CH_2)_n$ -,  $-(C_2-C_3)$ -alkylene- $O-(C_0-C_3)$ -alkylene-,  $-(C_2-C_3)$ -alkylene- $S(O)$ -,  $-(C_2-C_3)$ -alkylene- $S(O)_2$ -,  $-(CH_2)_m-NR^{10}-C(O)-O-(CH_2)_n$ -,  $-(C_2-C_3)$ -alkylene- $S(O)_2-NH-(R^{10})$ -,  $-(C_2-C_3)$ -alkylene- $N(R^{10})$ - or  $-(C_0-C_3)$ -alkylene- $C(O)-O-(CH_2)_m$ -,

20

25

wherein  $-(CH_2)_m$ - or  $-(CH_2)_n$ - are alkylene that is unsubstituted or mono-, di- or trisubstituted independently of one another by halogen,  $-NH_2$  or  $-OH$ , or  $-(C_3-C_6)$ -cycloalkylene, that is unsubstituted or mono-, di- or trisubstituted independently of one another by halogen,  $-NH_2$  or  $-OH$ ;

30

$R^1$  is hydrogen,  $-(C_1-C_4)$ -alkyl, wherein the alkyl is unsubstituted or substituted one to three times by  $R^{13}$ ,  $-(C_1-C_3)$ -alkylene- $C(O)-NH-R^0$ ,  $-(C_1-C_3)$ -alkylene- $C(O)-O-R^{15}$ , a monocyclic or bicyclic 6- to 14-membered aryl, wherein the aryl is mono-, di- or trisubstituted independently of one another by  $R^8$ ; a monocyclic or bicyclic 4- to 15-membered heterocyclyl, containing one, two, three or four heteroatoms chosen from nitrogen, sulfur or oxygen,   
 $-(C_1-C_3)$ -perfluoroalkylene,  $-(C_1-C_3)$ -alkylene- $S(O)-(C_1-C_4)$ -alkyl,   
 $-(C_1-C_3)$ -alkylene- $S(O)_2-(C_1-C_3)$ -alkyl,  $-(C_1-C_3)$ -alkylene- $S(O)_2-N(R^{4'})-R^{5'}$ ,   
 $-(C_1-C_3)$ -alkylene- $O-(C_1-C_4)$ -alkyl,  $-(C_0-C_3)$ -alkylene- $(C_3-C_8)$ -cycloalkyl, or   
 $-(C_0-C_3)$ -alkylene-het, wherein the het is a 3- to 7-membered cyclic residue, containing up to 1, 2, 3 or 4 heteroatoms chosen from nitrogen, sulfur or oxygen, and is unsubstituted or mono-, di- or trisubstituted independently of one another by  $R^{14}$ ,

$R^{4'}$  and  $R^{5'}$  are independent of one another are identical or different and are hydrogen atom or  $-(C_1-C_4)$ -alkyl,

$R^2$  is a direct bond or  $-(C_1-C_4)$ -alkylene, or

$R^1$  and  $R^3$  together with the atoms to which they are bonded form a 6- to 8-membered cyclic group, containing 1, 2, 3 or 4 heteroatoms chosen from nitrogen, sulfur or oxygen, wherein said cyclic group is unsubstituted or mono-, di- or trisubstituted independently of one another by  $R^{14}$ , or

$R^1-N-R^2-V$  form a 4- to 7-membered cyclic group, containing 1, 2, 3 or 4 heteroatoms chosen from nitrogen, sulfur or oxygen, and wherein said cyclic group is unsubstituted or mono-, di- or trisubstituted independently of one another by  $R^{14}$ ;

$R^{14}$  is halogen,  $-OH$ ,  $=O$ ,  $-(C_1-C_8)$ -alkyl,  $-(C_1-C_4)$ -alkoxy,  $-NO_2$ ,  $-C(O)-OH$ ,  $-CN$ ,  $-NH_2$ ,  $-C(O)-O-(C_1-C_4)$ -alkyl,  $-(C_0-C_8)$ -alkyl- $SO_2-(C_1-C_4)$ -alkyl,

$-(C_0-C_8)$ -alkyl- $SO_2-(C_1-C_3)$ -perfluoroalkyl,  $-(C_0-C_8)$ -alkyl- $SO_2-N(R^{18})-R^{21}$ ,   
 $-C(O)-NH-(C_1-C_8)$ -alkyl,  $-C(O)-N-[(C_1-C_8)$ -alkyl] $_2$ ,  $-NR^{18}-C(O)-NH-(C_1-C_8)$ -alkyl,   
 $-C(O)-NH_2$ ,  $-S-R^{18}$ , or  $-NR^{18}-C(O)-NH-[(C_1-C_8)$ -alkyl] $_2$ ,

wherein  $R^{18}$  and  $R^{21}$  are independently from each other hydrogen,  $-(C_1-C_3)$ -perfluoroalkyl or  $-(C_1-C_6)$ -alkyl;

- V is
- 1) a 3- to 7-membered cyclic residue, containing 1, 2, 3 or 4 heteroatoms chosen from nitrogen, sulfur or oxygen, wherein the cyclic residue is unsubstituted or mono-, di- or trisubstituted independently of one another by R14,
  - 2) a 6- to 14-membered aryl, wherein the aryl is unsubstituted or mono-, di- or trisubstituted independently of one another by R14, or
  - 3) a monocyclic or bicyclic 4- to 15-membered heterocyclyl, wherein the heterocyclyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R14;

G is a direct bond,  $-(CH_2)_m-NR^{10}-SO_2-NR^{10}-(CH_2)_n-$ ,  $-(CH_2)_m-CH(OH)-(CH_2)_n-$ ,  $-(CH_2)_m-$ ,  $-(CH_2)_m-O-(CH_2)_n-$ ,  $-(CH_2)_m-C(O)-NR^{10}-(CH_2)_n-$ ,  $-(CH_2)_m-SO_2-(CH_2)_n-$ ,  $-(CH_2)_m-NR^{10}-C(O)-NR^{10}-(CH_2)_n-$ ,  $-(CH_2)_m-NR^{10}-C(O)-(CH_2)_n-$ ,  $-(CH_2)_m-C(O)-(CH_2)_n-$ ,  $-(CH_2)_m-S-(CH_2)_n-$ ,  $-(CH_2)_m-SO_2-NR^{10}-(CH_2)_n-$ ,  $-(CH_2)_m-NR^{10}-SO_2-(CH_2)_n-$ ,  $-(CH_2)_m-NR^{10}-$ ,  $-(CH_2)_m-O-C(O)-NR^{10}-(CH_2)_n-$  or  $-(CH_2)_m-NR^{10}-C(O)-O-(CH_2)_n-$ ;

n and m are independently of one another identical or different and are the integers zero, 1, 2, 3, 4, 5 or 6;


- M is
- 1) hydrogen,
  - 2)  $-(C_1-C_8)$ -alkyl, wherein the alkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R14,
  - 3)  $-C(O)-N(R^{11})-R^{12}$ ,
  - 4)  $-(CH_2)_m-NR^{10}$ ,
  - 5) a 6- to 14-membered aryl, wherein the aryl is unsubstituted or mono-, di- or trisubstituted independently of one another by R14,
  - 6) a monocyclic or bicyclic 4- to 15-membered heterocyclyl, wherein the heterocyclyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R14,
  - 7)  $-(C_3-C_8)$ -cycloalkyl, wherein the cycloalkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R14, or
  - 8) a 3- to 7-membered cyclic residue, containing 1, 2, 3 or 4 heteroatoms chosen from nitrogen, sulfur or oxygen, wherein said cyclic residue is unsubstituted or mono-, di- or trisubstituted independently of one another by R14;

R3 is 1) hydrogen,

- 2) halogen,
- 3)  $-(C_1-C_4)$ -alkyl, wherein the alkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R13,
- 4)  $-(C_1-C_3)$ -perfluoroalkyl,
- 5 5) phenyl, wherein the phenyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R13,
- 6)  $-(C_0-C_4)$ -alkylene-O-R19,
- 7)  $-NO_2$ ,
- 8)  $-CN$ ,
- 10 9)  $-SO_s-R^{11}$ , wherein s is 1 or 2,
- 10)  $-SO_t-N(R^{11})-R^{12}$ , wherein t is 1 or 2,
- 11)  $-(C_0-C_4)$ -alkylene-C(O)-R<sup>11</sup>,
- 12)  $-(C_0-C_4)$ -alkylene-C(O)-O-R<sup>11</sup>,
- 13)  $-(C_0-C_4)$ -alkylene-C(O)-N(R<sup>11</sup>)-R<sup>12</sup>,
- 15 14)  $-(C_0-C_4)$ -alkylene-N(R<sup>11</sup>)-R<sup>12</sup>,
- 15)  $-NR^{10}-SO_2-R^{10}$ ,
- 16)  $-S-R^{10}$ ,
- 17)  $-(C_0-C_2)$ alkylene-C(O)-O-(C<sub>2</sub>-C<sub>4</sub>)-alkylene-O-C(O)-(C<sub>1</sub>-C<sub>4</sub>)-alkyl,
- 18)  $-C(O)-O-C(R^{15}, R^{16})-O-C(O)-R^{17}$ ,
- 20 19)  $-(C_0-C_2)$ alkylene-C(O)-O-(C<sub>2</sub>-C<sub>4</sub>)-alkylene-O-C(O)-O-(C<sub>1</sub>-C<sub>6</sub>)-alkyl,
- 20)  $-C(O)-O-C(R^{15}, R^{16})-O-C(O)-O-R^{17}$ ,
- 21)  $-(C_0-C_4)$ -alkylene-(C<sub>6</sub>-C<sub>14</sub>)-aryl, wherein aryl is mono-, di- or trisubstituted independently of one another by R13,
- 22)  $-(C_0-C_4)$ -alkylene-(C<sub>4</sub>-C<sub>15</sub>)-heterocyclyl, wherein the heterocyclyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R13
- 25 23)  $-(C_0-C_4)$ -alkylene-(C<sub>3</sub>-C<sub>8</sub>)-cycloalkyl, wherein the cycloalkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R13,
- 24)  $-(C_0-C_4)$ -alkylene-het, wherein the het is unsubstituted or mono-, di- or trisubstituted independently of one another by R13,
- 30 25)  $-(C_0-C_4)$ -alkylene-O-CH<sub>2</sub>-(C<sub>1</sub>-C<sub>3</sub>)-perfluoroalkylene-CH<sub>2</sub>-O-(C<sub>0</sub>-C<sub>4</sub>)-alkyl,
- 26)  $-SO_w-N(R^{11})-R^{13}$ , wherein w is 1 or 2,
- 27)  $-(C_0-C_4)$ -alkylene-C(O)-N(R<sup>11</sup>)-R<sup>13</sup>,

28)  $-(C_0-C_4)\text{-alkylene-N(R}^{11})\text{-R}^{13}$ , or

29) a residue selected from the group consisting of



R19 is a) hydrogen,

10 b)  $-(C_1-C_4)\text{-alkyl}$ , wherein the alkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R13,

c)  $-\text{CF}_3$ , or

d)  $-\text{CHF}_2$ ,

15 or two -OR19 residues and adjacent atoms through which they are attached may form together a 5- or 6- membered ring, that is unsubstituted or substituted one, two, three or four times by R13;

R11 and R12 are independently of one another identical or different and are

1) hydrogen,

20 2)  $-(C_1-C_6)\text{-alkyl}$ , wherein the alkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R13,


3)  $-(C_0-C_6)\text{-alkyl-(C}_3\text{-C}_8\text{)-cycloalkyl}$ ,


4)  $-\text{SO}_t\text{-R}^{10}$ , wherein t is 1 or 2,

- 5)  $-(C_0-C_6)\text{-alkyl-(C}_6\text{-C}_{14}\text{)-aryl}$ , wherein the alkyl and aryl independently from one another are unsubstituted or mono-, di- or trisubstituted by R<sup>13</sup>,
- 6)  $-(C_1-C_3)\text{-perfluoroalkyl}$ ,
- 7)  $-O-R^{17}$ , or
- 8)  $-(C_0-C_6)\text{-alkyl-(C}_4\text{-C}_{15}\text{)-heterocyclyl}$ , wherein the alkyl and heterocyclyl independently from one another are unsubstituted or mono-, di- or trisubstituted by R<sup>13</sup>, or

10 R11 and R12 together with the nitrogen atom to which they are bonded form a 4- to 7-membered monocyclic heterocyclic ring which in addition to the nitrogen atom contain one or two identical or different ring heteroatoms chosen from oxygen, sulfur and nitrogen; wherein said heterocyclic ring is unsubstituted or mono-, di- or trisubstituted independently of one another by R13;

15 R13 is halogen, -NO<sub>2</sub>, -CN, =O, -OH, -CF<sub>3</sub>, -C(O)-O-R<sup>10</sup>, -C(O)-N(R<sup>10</sup>)-R<sup>20</sup>,  
-N(R<sup>10</sup>)-R<sup>20</sup>, -(C<sub>3</sub>-C<sub>8</sub>)-cycloalkyl, -(C<sub>0</sub>-C<sub>3</sub>)-alkylene-O-R<sup>10</sup>, -Si-(CH<sub>3</sub>)<sub>3</sub>,  
-N(R<sup>10</sup>)-S(O)<sub>u</sub>-R<sup>10</sup>, wherein u is 1 or 2, -S-R<sup>10</sup>, -SO<sub>r</sub>-R<sup>10</sup>, wherein r is 1 or 2, -S(O)<sub>v</sub>-  
N(R<sup>10</sup>)-R<sup>20</sup>, wherein v is 1 or 2, -C(O)-R<sup>10</sup>, -(C<sub>1</sub>-C<sub>8</sub>)-alkyl, -(C<sub>1</sub>-C<sub>8</sub>)-alkoxy, phenyl,  
phenyloxy-, -O-CF<sub>3</sub>, -(C<sub>0</sub>-C<sub>4</sub>)-alkyl-C(O)-O-C(R<sup>15</sup>, R<sup>16</sup>)-O-C(O)-R<sup>17</sup>,  
-(C<sub>1</sub>-C<sub>4</sub>)-alkoxy-phenyl, -(C<sub>0</sub>-C<sub>4</sub>)-alkyl-C(O)-O-C(R<sup>15</sup>, R<sup>16</sup>)-O-C(O)-O-R<sup>17</sup>,  
20 -(C<sub>1</sub>-C<sub>3</sub>)-perfluoroalkyl, -O-R<sup>15</sup>, -NH-C(O)-NH-R<sup>10</sup>, -NH-C(O)-O-R<sup>10</sup> or a residue  
selected from the group consisting of





R<sup>10</sup> and R<sup>20</sup> are independently of one another hydrogen, -(C<sub>1</sub>-C<sub>6</sub>)-alkyl, -(C<sub>0</sub>-C<sub>4</sub>)-alkyl-OH,  
 5 -(C<sub>0</sub>-C<sub>4</sub>)-alkyl-O-(C<sub>1</sub>-C<sub>4</sub>)-alkyl or -(C<sub>1</sub>-C<sub>3</sub>)-perfluoroalkyl;

R<sup>15</sup> and R<sup>16</sup> are independently of one another hydrogen, -(C<sub>1</sub>-C<sub>6</sub>)-alkyl, or together with the carbon  
 atom to which they are bonded form a 3- to 6 membered carbocyclic ring which is  
 unsubstituted or substituted one to three times by R<sup>10'</sup> and

R<sup>17</sup> is -(C<sub>1</sub>-C<sub>6</sub>)-alkyl, -(C<sub>1</sub>-C<sub>6</sub>)-alkyl-OH, -(C<sub>1</sub>-C<sub>6</sub>)-alkyl-O-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, -(C<sub>3</sub>-C<sub>8</sub>)-cycloalkyl,  
 -(C<sub>1</sub>-C<sub>6</sub>)-alkyl-O-(C<sub>1</sub>-C<sub>8</sub>)-alkyl-(C<sub>3</sub>-C<sub>8</sub>)-cycloalkyl, -(C<sub>1</sub>-C<sub>6</sub>)-alkyl-(C<sub>3</sub>-C<sub>8</sub>)-cycloalkyl,  
 wherein the cycloalkyl is unsubstituted or substituted one, two or three times by -OH,  
 -O-(C<sub>1</sub>-C<sub>4</sub>)-alkyl or R<sup>10</sup>;

or a stereoisomer or a mixture of stereoisomers thereof in any ratio, or a physiologically acceptable  
 salt thereof.

2. The compound according to claim 1, wherein

R<sup>0</sup> as 1) is phenyl, naphthyl, biphenyl, anthryl or fluorenyl, each of which is mono-, di- or  
 20 trisubstituted independently of one another by R<sup>8</sup>, or

3) is acridinyl, azabenzimidazolyl, azaspirodecanyl, azepinyl, azetidyl, aziridinyl,  
 benzimidazolyl, benzofuranyl, benzothiofuranyl, benzothiophenyl, benzoxazolyl,  
 benzthiazolyl, benztriazolyl, benztetrazolyl, benzisoxazolyl, benzisothiazolyl, carbazolyl,  
 4aH-carbazolyl, carbolinyl, chromanyl, chromenyl, cinnolinyl, decahydrochinolinyl, 4,5-  
 25 dihydrooxa-zolinyl, dioxazolyl, dioxazinyl, 1,3-dioxolanyl, 1,3-dioxolenyl, 6H-1,5,2-  
 dithiazinyl, dihydrofuro[2,3-b]-tetrahydrofuranyl, furanyl, furazanyl, imidazolidinyl,  
 imidazolyl, 1H-indazolyl, indolinyl, indoliziny, indolyl, 3H-indolyl,  
 isobenzofuranyl, isochromanyl, isoindazolyl, isoindolinyl, isoindolyl, isoquinolinyl,  
 isothiazolyl, isothiazolidinyl, isothiazolinyl, isoxazolyl, isoxazolinyl, isoxazolidinyl, 2-



isoxazolinyl, ketopiperazinyl, morpholinyl, naphthyridinyl, octahydroisoquinolinyl, oxadiazolyl, 1,2,3-oxadiazolyl, 1,2,4-oxadiazolyl, 1,2,5-oxadiazolyl, 1,3,4-oxadiazolyl, 1,2-oxa-thiepanyl, 1,2-oxathiolanyl, 1,4-oxazepanyl, 1,2-oxazinyl, 1,3-oxazinyl, 1,4-oxazinyl, oxazolidinyl, oxazoliny, oxazolyl, phenanthridinyl, phenanthrolinyl, phenazinyl, 5 phenothiazinyl, phenoxathiinyl, phenoxazinyl, phthalazinyl, piperazinyl, piperidinyl, pteridinyl, purinyl, pyranyl, pyrazinyl, pyrazolidinyl, pyrazolinyl, pyrazolyl, pyridazinyl, pyridooxazolyl, pyridoimidazolyl, pyridothiazolyl, pyridyl, pyrimidinyl, pyrrolidinyl, pyrrolidinonyl, pyrrolinyl, 2H-pyrrolyl, pyrrolyl, quinazolinyl, quinolinyl, 4H-quinoliziny, quinoxaliny, quinuclidinyl, tetrahydrofuranyl, tetrahydroisoquinolinyl, tetrahydroquinolinyl, 10 1,4,5,6-tetrahydro-pyridazinyl, tetrahydropyridinyl, tetrahydrothiophenyl, tetrazinyl, tetrazolyl, 6H-1,2,5-thiadiazinyl, 1,2,3-thiadiazolyl, 1,2,4-thiadiazolyl, 1,2,5-thiadiazolyl, 1,3,4-thiadiazolyl, thianthrenyl, 1,2-thiazinyl, 1,3-thiazinyl, 1,4-thiazinyl, 1,3-thiazolyl, thiazolyl, thiazolidinyl, thiazolinyl, thienyl, thietanyl, thienothiazolyl, thienooxazolyl, thienoimidazolyl, thietanyl, thiomorpholinyl, thiophenolyl, thiophenyl, thiopyranyl, 1,2,3-15 triazinyl, 1,2,4-triazinyl, 1,3,5-triazinyl, 1,2,3-triazolyl, 1,2,4-triazolyl, 1,2,5-triazolyl, 1,3,4-triazolyl or xanthenyl, each of which is unsubstituted or mono-, di- or trisubstituted independently of one another by R<sub>8</sub>, and is additionally substituted by acridinyl, azabenzimidazolyl, azaspirodecanyl, azepinyl, azetidiny, aziridinyl, benzimidazolyl, benzofuranyl, benzothiofuranyl, benzothiophenyl, benzoxazolyl, benzthiazolyl, benztriazolyl, 20 benztetrazolyl, benzisoxazolyl, benzisothiazolyl, carbazolyl, 4aH-carbazolyl, carbolinyl, chromanyl, chromenyl, cinnolinyl, decahydrochinolinyl, 4,5-dihydrooxa-zolinyl, dioxazolyl, dioxazinyl, 1,3-dioxolanyl, 1,3-dioxolenyl, 6H-1,5,2-dithiazinyl, dihydrofuro[2,3-b]-tetrahydrofuranyl, furanyl, furazanyl, imidazolidinyl, imidazoliny, imidazolyl, 1H-indazolyl, indolinyl, indoliziny, indolyl, 3H-indolyl, isobenzofuranyl, isochromanyl, isoindazolyl, 25 isoindolinyl, isoindolyl, isoquinolinyl, isothiazolyl, isothiazolidinyl, isothiazolinyl, isoxazolyl, isoxazolinyl, isoxazolidinyl, 2-isoxazolinyl, ketopiperazinyl, morpholinyl, naphthyridinyl, octahydroisoquinolinyl, oxadiazolyl, 1,2,3-oxadiazolyl, 1,2,4-oxadiazolyl, 1,2,5-oxadiazolyl, 1,3,4-oxadiazolyl, 1,2-oxa-thiepanyl, 1,2-oxathiolanyl, 1,4-oxazepanyl, 1,2-oxazinyl, 1,3-oxazinyl, 1,4-oxazinyl, oxazolidinyl, oxazoliny, oxazolyl, phenanthridinyl, phenanthrolinyl, 30 phenazinyl, phenothiazinyl, phenoxathiinyl, phenoxazinyl, phthalazinyl, piperazinyl, piperidinyl, pteridinyl, purinyl, pyranyl, pyrazinyl, pyrazolidinyl, pyrazolinyl, pyrazolyl, pyridazinyl, pyridooxazolyl, pyridoimidazolyl, pyridothiazolyl, pyridyl, pyrimidinyl, pyrrolidinyl, pyrrolidinonyl, pyrrolinyl, 2H-pyrrolyl, pyrrolyl, quinazolinyl, quinolinyl, 4H-quinoliziny, quinoxaliny, quinuclidinyl, tetrahydrofuranyl, tetrahydroisoquinolinyl, 35 tetrahydroquinolinyl, 1,4,5,6-tetrahydro-pyridazinyl, tetrahydropyridinyl, tetrahydrothiophenyl, tetrazinyl, tetrazolyl, 6H-1,2,5-thiadiazinyl, 1,2,3-thiadiazolyl, 1,2,4-thiadiazolyl, 1,2,5-thiadiazolyl, 1,3,4-thiadiazolyl, thianthrenyl, 1,2-thiazinyl, 1,3-thiazinyl,

1,4-thiazinyl, 1,3-thiazolyl, thiazolyl, thiazolidinyl, thiazolinyl, thienyl, thietanyl, thienothiazolyl, thienooxazolyl, thienoimidazolyl, thietanyl, thiomorpholinyl, thiophenolyl, thiophenyl, thiopyranyl, 1,2,3-triazinyl, 1,2,4-triazinyl, 1,3,5-triazinyl, 1,2,3-triazolyl, 1,2,4-triazolyl, 1,2,5-triazolyl, 1,3,4-triazolyl or xanthenyl, each of which is unsubstituted or mono-,  
 5 di- or trisubstituted independently of one another by R<sub>8</sub>;

the substructure D is azetidine, azetine, azocane, azocane-2-one, cyclobutyl, cyclooctane, cyclooctene, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, 1,4-diazepane, 1,2-diazepine, 1,3-diazepine, 1,4-diazepine, [1,4]diazocane, [1,2]diazocan-3-one, [1,3]diazocan-2-one, dioxazole,  
 10 dioxazine, dioxole, 1,3-dioxolene, 1,3-dioxolane, furan, imidazole, imidazoline, imidazolidine, isothiazole, isothiazolidine, isothiazoline, isoxazole, isoxazoline, isoxazolidine, 2-isoxazoline, ketopiperazine, morpholine, 1,2-oxa-thiepane, 1,2-oxathiolan, 1,2-oxazine, 1,3-oxazine, 1,4-oxazine, oxazole, [1,4]oxazocane, [1,3]oxazocan-2-one, oxetan, oxocane, oxocan-2-one, piperazine, piperidine, pyran, pyrazine, pyrazole, pyrazoline, pyrazolidine,  
 15 pyridazine, pyridine, pyrimidine, pyrrole, pyrrolidine, pyrrolidinone, pyrroline, 5,6,7,8-tetrahydro-1H-azocin-2-one, tetrahydrofuran, tetrahydropyran, tetrahydropyridine, tetrazine, thiadiazine, thiadiazole, 1,2-thiazine, 1,3-thiazine, 1,4-thiazine, 1,3-thiazole, thiazole, thiazolidine, thiazoline, thietan, thiocane, thiocane-1,1-dioxide, thiocane-1-oxide, thiocan-2-one, thiomorpholine, thiophene, thiopyran, 1,2,3-triazine, 1,2,4-triazine, 1,3,5-triazine, 1,2,3-triazole or 1,2,4-triazole, and is unsubstituted or substituted 1, 2, 3, 4, 5 or 6 times by R<sub>3</sub>, or is  
 20 substituted 1 or 2 times by =O;

R<sup>1</sup> as a monocyclic or bicyclic 6- to 14-membered aryl is phenyl, naphthyl, biphenyl, anthryl or fluorenyl, each of which is mono-, di- or trisubstituted independently of one another by R<sub>8</sub>, or  
 25

-(C<sub>0</sub>-C<sub>3</sub>)-alkylene-het, then het is azepine, azetidine, aziridine, azirine, 1,4-diazapane, 1,2-diazepine, 1,3-diazepine, 1,4-diazepine, diaziridine, diazirine, dioxazole, dioxazine, dioxole, 1,3-dioxolene, 1,3-dioxolane, furan, imidazole, imidazoline, imidazolidine, isothiazole, isothiazolidine, isothiazoline, isoxazole, isoxazoline, isoxazolidine, 2-isoxazoline,  
 30 ketopiperazine, morpholine, 1,4-oxazepane, 1,2-oxa-thiepane, 1,2-oxathiolane, 1,2-oxazine, 1,3-oxazine, 1,4-oxazine, oxazole, oxaziridine, oxirane, piperazine, piperidine, pyran, pyrazine, pyrazole, pyrazoline, pyrazolidine, pyridazine, pyridine, pyrimidine, pyrrole, pyrrolidine, pyrrolidinone, pyrroline, tetrahydropyridine, tetrazine, tetrazole, thiadiazine, thiadiazole, 1,2-thiazine, 1,3-thiazine, 1,4-thiazine, 1,3-thiazole, thiazole, thiazolidine,  
 35 thiazoline, thienyl, thietan, thiomorpholine, thiopyran, 1,2,3-triazine, 1,2,4-triazine, 1,3,5-

triazine, 1,2,3-triazole or 1,2,4-triazole, which is unsubstituted or mono-, di- or trisubstituted independently of one another by R14, or

R<sup>1</sup> and R<sup>3</sup> with the atoms to which they are bonded form form azocane, azocane-2-one, 1,2-diazepine, 1,3-diazepine, 1,4-diazepine, [1,4]diazocane, [1,2]diazocan-3-one, [1,3]diazocan-2-one, dioxazine, [1,4]dioxocane, dioxole, ketopiperazine, morpholine, 1,2-oxazine, 1,3-oxazine, 1,4-oxazine, [oxocane, oxocan-2-one, piperazine, piperidine, pyran, pyrazine, pyridazine, pyrimidine or 5,6,7,8-tetrahydro-1H-azocin-2-one, each of which is unsubstituted or mono-, di- or trisubstituted independently of one another by R14, or

R<sup>1</sup>-N-R<sup>2</sup>-V form azepine, azetidine, dioxazole, dioxazine, 1,2-diazepine, 1,3-diazepine, 1,4-diazepine, imidazole, imidazoline, imidazolidine, isothiazole, isothiazolidine, isothiazoline, isoxazole, isoxazoline, isoxazolidine, 2-isoxazoline, ketopiperazine, morpholine, oxazole, piperazine, piperidine, pyrazine, pyrazole, pyrazoline, pyrazolidine, pyridazine, pyridine, pyrimidine, pyrrole, pyrrolidine, pyrrolidinone, pyrroline, tetrahydropyridine, tetrazine, tetrazole, thiazole, thiadiazole, thiazolidine, thiazoline, thiomorpholine, 1,2,3-triazine, 1,2,4-triazine, 1,3,5-triazine, 1,2,3-triazole or 1,2,4-triazole, each of which is unsubstituted or mono-, di- or trisubstituted independently of one another by R14;

V is 2) phenyl, naphthyl, biphenyl, anthryl or fluorenyl, each of which is mono-, di- or trisubstituted independently of one another by R14, or

3) acridinyl, 8-aza-bicyclo[3.2.1]oct-3-yl, azaindole (1H-pyrrolopyridine), azabenzimidazolyl, azaspirodecanyl, azepinyl, azetidyl, aziridinyl, benzimidazolyl, benzofuranyl, benzothiofuranyl, benzothiophenyl, benzoxazolyl, benzthiazolyl, benztriazolyl, benztetrazolyl, benzisoxazolyl, benzisothiazolyl, carbazolyl, 4aH-carbazolyl, carbolinyl, chromanyl, chromenyl, cinnolyl, decahydrochinolyl, 1,4-diazepane, 4,5-dihydrooxazolyl, dioxazolyl, dioxazinyl, 1,3-dioxolanyl, 1,3-dioxolenyl, 6H-1,5,2-dithiazinyl, dihydrofuro[2,3-b]-tetrahydrofuranlyl, furanyl, furazanyl, imidazolidinyl, imidazolyl, imidazolyl, 1H-indazolyl, indolyl, indolizyl, indolyl, 3H-indolyl, isobenzofuranyl, isochromanyl, isoindazolyl, isoindolyl, isoindolyl, isoquinolyl, isothiazolyl, isothiazolidinyl, isothiazolyl, isoxazolyl, isoxazolyl, isoxazolidinyl, 2-isoxazolyl, ketopiperazinyl, morpholinyl, naphthyridinyl, octahydroisoquinolyl, oxadiazolyl, 1,2,3-oxadiazolyl, 1,2,4-oxadiazolyl, 1,2,5-oxadiazolyl, 1,3,4-oxadiazolyl, 1,2-oxa-thiepanyl, 1,2-oxathiolanyl, 1,4-oxazepanyl, 1,2-oxazinyl, 1,3-oxazinyl, 1,4-oxazinyl, oxazolidinyl, oxazolyl, oxazolyl, phenanthridinyl, phenanthrolinyl, phenazinyl, phenothiazinyl, phenoxathiinyl, phenoxazinyl, phthalazinyl, piperazinyl, piperidinyl, pteridinyl, purinyl,

pyranyl, pyrazinyl, pyrazolidinyl, pyrazolinyl, pyrazolyl, pyridazinyl, pyridooxazolyl, pyridoimidazolyl, pyridothiazolyl, pyridyl, pyrimidinyl, pyrrolidinyl, pyrrolidinonyl, pyrrolinyl, 2H-pyrrolyl, pyrrolyl, quinazolinyl, quinolinyl, 4H-quinoliziny, quinoxaliny, quinuclidinyl, tetrahydrofuranyl, tetrahydroisochinoliny, tetrahydrochinoliny, 1,4,5,6-  
 5 tetrahydro-pyridazinyl, tetrahydropyridinyl, tetrahydrothiophenyl, tetrazinyl, tetrazolyl, 6H-1,2,5-thiadiazinyl, 1,2,3-thiadiazolyl, 1,2,4-thiadiazolyl, 1,2,5-thiadiazolyl, 1,3,4-thiadiazolyl, thianthrenyl, 1,2-thiazinyl, 1,3-thiazinyl, 1,4-thiazinyl, 1,3-thiazolyl, thiazolyl, thiazolidinyl, thiazolinyl, thienyl, thietanyl, thienothiazolyl, thienooxazolyl, thienoimidazolyl, thietanyl, thiomorpholinyl, 1,6-thiomorpholinyl, thiophenyl, thiopyranyl, 1,2,3-triazinyl, 1,2,3-  
 10 triazolyl, 1,2,3-triazolyl, 1,2,4-triazolyl, 1,2,5-triazolyl, 1,3,4-triazolyl and xanthenyl, each of which is mono-, di- or trisubstituted independently of one another by R14;

M is 1) hydrogen,  
 2)  $-(C_1-C_8)$ -alkyl, wherein the alkyl is unsubstituted or mono-, di- or trisubstituted  
 15 independently of one another by R14,  
 3)  $-C(O)-N(R_{11})-R_{12}$ ,  
 4)  $-(CH_2)_m-NR^{10}$ ,  
 5)  $-(C_6-C_{14})$ -aryl, wherein the aryl is as defined above and wherein aryl is unsubstituted or mono-, di- or trisubstituted independently of one another by R14,  
 20 6)  $-(C_4-C_{15})$ -heterocyclyl, wherein the heterocyclyl is as defined above and is unsubstituted or mono-, di- or trisubstituted independently of one another by R14, or  
 7)  $-(C_3-C_8)$ -cycloalkyl, wherein the cycloalkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R14;

25 R3 as 25) is  $-(C_0-C_3)$ -alkylene-O-CH<sub>2</sub>-(C<sub>1</sub>-C<sub>3</sub>)-perfluoroalkylene-CH<sub>2</sub>-O-(C<sub>0</sub>-C<sub>3</sub>)-alkyl;

two -OR<sub>19</sub> residues and adjacent atoms through which they are attached may form together a 1,3-dioxole ring or a 2,3-dihydro-[1,4]dioxine ring, each of which is substituted one, two, three or four times by R<sub>13</sub>;

30

R<sub>11</sub> and R<sub>12</sub> together with the nitrogen atom to which they are bonded may form azepine, azetidine, dioxazole, dioxazine, 1,4-diazepane, 1,2-diazepine, 1,3-diazepine, 1,4-diazepine, imidazole, imidazoline, imidazolidine, isothiazole, isothiazolidine, isothiazoline, isoxazole, isoxazoline, isoxazolidine, 2-isoxazoline, ketopiperazine, morpholine, [1,4]oxazepane, oxazole,  
 35 piperazine, piperidine, pyrazine, pyrazole, pyrazoline, pyrazolidine, pyridazine, pyridine,

pyrimidine, pyrrole, pyrrolidine, pyrrolidinone, pyrroline, tetrahydropyridine, tetrazine, tetrazole, thiazole, thiadiazole, thiazolidine, thiazoline, thiomorpholine, thiophene, 1,2,3-triazine, 1,2,4-triazine, 1,3,5-triazine, 1,2,3-triazole or 1,2,4-triazole, each of which is unsubstituted or mono-, di- or trisubstituted independently of one another by R<sup>13</sup>;

5

R<sup>15</sup> and R<sup>16</sup> are independently of one another hydrogen, or -(C<sub>1</sub>-C<sub>6</sub>)-alkyl, or together with the carbon atom to which they are bonded form cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl, wherein each ring is unsubstituted or substituted one to three times by R<sup>10</sup>; and

10 R<sup>17</sup> is -(C<sub>1</sub>-C<sub>6</sub>)-alkyl, -(C<sub>1</sub>-C<sub>6</sub>)-alkyl-OH, -(C<sub>1</sub>-C<sub>6</sub>)-alkyl-O-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, -(C<sub>1</sub>-C<sub>6</sub>)-alkyl-O-(C<sub>1</sub>-C<sub>8</sub>)-alkyl-(C<sub>3</sub>-C<sub>8</sub>)-cycloalkyl, -(C<sub>0</sub>-C<sub>6</sub>)-alkyl-(C<sub>3</sub>-C<sub>8</sub>)-cycloalkyl, wherein the cycloalkyl is unsubstituted or substituted one, two or three times by -OH, -O-(C<sub>1</sub>-C<sub>4</sub>)-alkyl or R<sup>10</sup>.

15 3. The compound according to claim 1, wherein

R<sup>0</sup> as 1) is phenyl, naphthyl, biphenyl, anthryl or fluorenyl, each of which is mono-, di- or trisubstituted independently of one another by R<sup>8</sup>, or

20 3) is azabenzimidazolyl, benzimidazolyl, 1,3-benzodioxolyl, benzofuranyl, benzothiazolyl, benzothiophenyl, benzoxazolyl, chromanyl, cinnolyl, 2-furyl, 3-furyl; imidazolyl, indolyl, indazolyl, isochromanyl, isoindolyl, isoquinolyl, isothiazolyl, isoxazolyl, oxazolyl, phthalazinyl, pteridyl, purinyl, pyrazinyl, pyrazolyl, pyridazinyl, pyridoimidazolyl, pyridopyridinyl, pyridopyrimidinyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, pyrimidinyl, pyrrolyl; 2-pyrrolyl, 3-pyrrolyl, quinolyl, quinazolyl, quinoxalyl, tetrazolyl, thiazolyl, 2-thienyl or 3-thienyl,

25 each of which is additionally substituted by acridinyl, azabenzimidazolyl, azaspirodecanyl, azepinyl, azetidyl, aziridinyl, benzimidazolyl, benzofuranyl, benzothiofuranyl, benzothiophenyl, benzoxazolyl, benzthiazolyl, benztriazolyl, benztetrazolyl, benzisoxazolyl, benzisothiazolyl, carbazolyl, 4aH-carbazolyl, carbolinyl, chromanyl, chromenyl, cinnolyl, decahydrochinolyl, 4,5-dihydrooxa-zolyl, dioxazolyl, dioxazinyl, 1,3-dioxolanyl, 1,3-dioxolenyl, 6H-1,5,2-dithiazinyl, dihydrofuro[2,3-b]-tetrahydrofuranyl, furanyl, furazanyl, imidazolidinyl, imidazolyl, imidazolyl, 1H-indazolyl, indolyl, indolizyl, indolyl, 3H-indolyl, isobenzofuranyl, isochromanyl, isoindazolyl, isoindolyl, isoindolyl, isoquinolyl (benzimidazolyl), isothiazolyl, isothiazolidinyl, isothiazolyl, isoxazolyl, isoxazolyl, isoxazolidinyl, 2-isoxazolyl, ketopiperazinyl, morpholyl, naphthyridinyl,

35 octahydroisoquinolyl, oxadiazolyl, 1,2,3-oxadiazolyl, 1,2,4-oxadiazolyl, 1,2,5-oxadiazolyl,

1,3,4-oxadiazolyl, 1,2-oxa-thiepanyl, 1,2-oxathiolanyl, 1,4-oxazepanyl, 1,2-oxazinyl, 1,3-oxazinyl, 1,4-oxazinyl, oxazolidinyl, oxazolanyl, oxazolyl, phenanthridinyl, phenanthrolinyl, phenazinyl, phenothiazinyl, phenoxathiinyl, phenoxazinyl, phthalazinyl, piperazinyl, piperidinyl, pteridinyl, purinyl, pyranyl, pyrazinyl, pyrazolidinyl, pyrazolinyl, pyrazolyl, pyridazinyl, pyridooxazolyl, pyridoimidazolyl, pyridothiazolyl, pyridyl, pyrimidinyl, pyrrolidinyl, pyrrolidinonyl, pyrrolinyl, 2H-pyrrolyl, pyrrolyl, quinazolinyl, quinolinyl, 4H-quinoliziny, quinoxalanyl, quinuclidinyl, tetrahydrofuranly, tetrahydroisochinoliny, tetrahydrochinoliny, 1,4,5,6-tetrahydro-pyridazinyl, tetrahydropyridinyl, tetrahydrothiophenyl, tetrazinyl, tetrazolyl, 6H-1,2,5-thiadiazinyl, 1,2,3-thiadiazolyl, 1,2,4-thiadiazolyl, 1,2,5-thiadiazolyl, 1,3,4-thiadiazolyl, thianthrenyl, 1,2-thiazinyl, 1,3-thiazinyl, 1,4-thiazinyl, 1,3-thiazolyl, thiazolyl, thiazolidinyl, thiazolinyl, thienyl, thietanyl, thienothiazolyl, thienooxazolyl, thienoimidazolyl, thietanyl, thiomorpholinyl, thiophenyl, thiopyranly, 1,2,3-triazinyl, 1,2,3-triazolyl, 1,2,3-triazolyl, 1,2,4-triazolyl, 1,2,5-triazolyl, 1,3,4-triazolyl and xanthenyl, each of which is unsubstituted or mono-, di- or trisubstituted independently of one another by R<sub>8</sub>;

R<sub>8</sub> as 1) is fluorine, chlorine or bromine,  
provided R<sub>8</sub> is at least one halogen, -C(O)-NH<sub>2</sub> or -O-(C<sub>1</sub>-C<sub>8</sub>)-alkyl residue;

substructure D is pyridyl, pyridyl-N-oxide pyridyl, pyrrolyl, furyl, thienyl, imidazolyl, pyrazolyl, oxazolyl, isoxazolyl, thiazolyl, triazolyl, isothiazolyl, thiadiazolyl, pyrimidinyl, pyridazinyl, or pyrazinyl, and is unsubstituted or substituted 1, 2, 3 or 4 times by R<sub>3</sub>, or is substituted 1 or 2 times by =O;

Q is a direct bond, -(C<sub>0</sub>-C<sub>2</sub>)-alkylene-C(O)-NR<sup>10</sup>-, -NR<sup>10</sup>-C(O)-NR<sup>10</sup>-, -NR<sup>10</sup>-C(O)-, -SO<sub>2</sub>- or -(C<sub>1</sub>-C<sub>6</sub>)-alkylene;

R<sup>1</sup> is hydrogen, -(C<sub>1</sub>-C<sub>4</sub>)-alkyl, wherein the alkyl is unsubstituted or substituted one to three times by R<sub>13</sub>, -(C<sub>1</sub>-C<sub>3</sub>)-alkylene-C(O)-NH-R<sup>0</sup>, -(C<sub>1</sub>-C<sub>3</sub>)-alkylene-C(O)-O-R<sup>15</sup>, -(C<sub>1</sub>-C<sub>3</sub>)-perfluoroalkylene, -(C<sub>1</sub>-C<sub>3</sub>)-alkylene-S(O)-(C<sub>1</sub>-C<sub>4</sub>)-alkyl, -(C<sub>1</sub>-C<sub>3</sub>)-alkylene-S(O)<sub>2</sub>-(C<sub>1</sub>-C<sub>3</sub>)-alkyl, -(C<sub>1</sub>-C<sub>3</sub>)-alkylene-S(O)<sub>2</sub>-N(R<sup>4'</sup>)-R<sup>5'</sup>, -(C<sub>1</sub>-C<sub>3</sub>)-alkylene-O-(C<sub>1</sub>-C<sub>4</sub>)-alkyl, -(C<sub>0</sub>-C<sub>3</sub>)-alkylene-(C<sub>3</sub>-C<sub>8</sub>)-cycloalkyl, or -(C<sub>0</sub>-C<sub>3</sub>)-alkylene-het, wherein the het is azepine, azetidine, aziridine, azirine, 1,4-diazepane, 1,2-diazepine, 1,3-diazepine, 1,4-diazepine, diaziridine, diazine, dioxazole, dioxazine,

dioxole, 1,3-dioxolene, 1,3-dioxolane, furan, imidazole, imidazoline, imidazolidine, isothiazole, isothiazolidine, isothiazoline, isoxazole, isoxazoline, isoxazolidine, 2-isoxazoline, ketopiperazine, morpholine, 1,2-oxa-thiepane, 1,2-oxathiolane, 1,4-oxazepane, 1,2-oxazine, 1,3-oxazine, 1,4-oxazine, oxazole, oxaziridine, oxirane, piperazine, piperidine, pyran, pyrazine, pyrazole, pyrazoline, pyrazolidine, pyridazine, pyridine, pyrimidine, pyrrole, pyrrolidine, pyrrolidinone, pyrroline, tetrahydropyridine, tetrazine, tetrazole, thiadiazine, thiadiazole, 1,2-thiazine, 1,3-thiazine, 1,4-thiazine, 1,3-thiazole, thiazole, thiazolidine, thiazoline, thienyl, thietan, thiomorpholine, thiopyran, 1,2,3-triazine, 1,2,4-triazine, 1,3,5-triazine, 1,2,3-triazole or 1,2,4-triazole, each of which is unsubstituted or mono-, di- or trisubstituted independently of one another by R14, or

R<sup>1</sup>-N-R<sup>2</sup>-V form azepine, azetidine, 1,4-diazepane, dioxazole, dioxazine, 1,2-diazepine, 1,3-diazepine, 1,4-diazepine, imidazole, imidazoline, imidazolidine, isothiazole, isothiazolidine, isothiazoline, isoxazole, isoxazoline, isoxazolidine, 2-isoxazoline, ketopiperazine, morpholine, 1,4-oxazepane, oxazole, piperazine, piperidine, pyrazine, pyrazole, pyrazoline, pyrazolidine, pyridazine, pyridine, pyrimidine, pyrrole, pyrrolidine, pyrrolidinone, pyrroline, tetrahydropyridine, tetrazine, tetrazole, thiazole, thiadiazole, thiazolidine, thiazoline, thiomorpholine, 1,2,3-triazine, 1,2,4-triazine, 1,3,5-triazine, 1,2,3-triazole or 1,2,4-triazole, each of which is unsubstituted or mono-, di- or trisubstituted independently of one another by R14;


V is 2) phenyl, wherein the phenyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R14, or


3) azaindole (1H-pyrrolopyridine), azepine, azetidine, aziridine, azirine, 1,4-diazepane, 1,2-diazepine, 1,3-diazepine, 1,4-diazepine, diaziridine, diazirine, dioxazole, dioxazine, dioxole, 1,3-dioxolene, 1,3-dioxolane, furan, imidazole, imidazoline, imidazolidine, isothiazole, isothiazolidine, isothiazoline, isoxazole, isoxazoline, isoxazolidine, 2-isoxazoline, ketopiperazine, morpholine, 1,2-oxa-thiepane, 1,2-oxathiolane, 1,4-oxazepane, 1,2-oxazine, 1,3-oxazine, 1,4-oxazine, oxazole, oxaziridine, oxirane, piperazine, piperidine, pyran, pyrazine, pyrazole, pyrazoline, pyrazolidine, pyridazine, pyridine, pyrimidine, pyrrole, pyrrolidine, pyrrolidinone, pyrroline, tetrahydropyridine, tetrazine, tetrazole, thiadiazine, thiadiazole, 1,2-thiazine, 1,3-thiazine, 1,4-thiazine, 1,3-thiazole, thiazole, thiazolidine, thiazoline, thienyl, thietan, thiomorpholine, thiopyran, 1,2,3-triazine, 1,2,4-triazine, 1,3,5-triazine, 1,2,3-triazole or 1,2,4-triazole, each of which is unsubstituted or mono-, di- or trisubstituted independently of one another by R14;

- M is
- 1) hydrogen,
  - 2)  $-(C_1-C_8)$ -alkyl, wherein the alkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R14,
  - 3)  $-C(O)-N(R^{11})-R^{12}$ ,
  - 5 4)  $-(CH_2)_m-NR^{10}$ ,
  - 5) phenyl or naphthyl, wherein the phenyl or naphthyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R14,
  - 6) azepane, azepine, 1,4-diazepane, 1,2-diazepine, 1,3-diazepine, 1,4-diazepine, imidazole, isothiazole, isoxazole, isoxazolidine, 2-isoxazoline, ketomorpholine,
  - 10 ketopiperazine, morpholine, oxazole, [1,4]-oxazepane, piperazine, piperazinone, piperidine, piperidinone, pyrazine, pyridazine, pyridazinone, pyridine, pyridone, pyrimidine, pyrrolidine, pyrrolidinone, tetrahydropyran, 1,4,5,6-tetrahydro-pyridazinyl, tetrazine, tetrazole, thiadiazole, thiazole, thiophene, thiomorpholine, 1,2,3-triazine, 1,2,4-triazine, 1,3,5-triazine, 1,2,3-triazole or 1,2,4-triazole, each of which is unsubstituted or mono-, di- or trisubstituted independently of one another by R14, or
  - 15 7)  $-(C_3-C_8)$ -cycloalkyl, wherein the cycloalkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R14;
- R3 is
- 20 1) hydrogen,
  - 2) halogen,
  - 3)  $-(C_1-C_4)$ -alkyl, wherein the alkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R13,
  - 4)  $-(C_1-C_3)$ -perfluoroalkyl,
  - 5) phenyl, wherein the phenyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R13,
  - 25 6)  $-(C_0-C_4)$ -alkylene-O-R<sup>19</sup>,
  - 8) -CN,
  - 9)  $-SO_s-R^{11}$ , wherein s is 1 or 2,
  - 10)  $-SO_t-N(R^{11})-R^{12}$ , wherein t is 1 or 2,
  - 30 11)  $-(C_0-C_4)$ -alkylene-C(O)-R<sup>11</sup>,
  - 12)  $-(C_0-C_4)$ -alkylene-C(O)-O-R<sup>11</sup>,
  - 13)  $-(C_0-C_4)$ -alkylene-C(O)-N(R<sup>11</sup>)-R<sup>12</sup>,
  - 14)  $-(C_0-C_4)$ -alkylene-N(R<sup>11</sup>)-R<sup>12</sup>,



- 15)  $-\text{NR}^{10}-\text{SO}_2-\text{R}^{10}$ ,  
 17)  $-(\text{C}_0-\text{C}_2)\text{-alkylene-C(O)-O-(C}_2\text{-C}_4\text{)-alkylene-O-C(O)-(C}_1\text{-C}_4\text{)-alkyl}$ ,  
 18)  $-\text{C(O)-O-C(R}^{15}, \text{R}^{16}\text{)-O-C(O)-R}^{17}$ ,  
 19)  $-(\text{C}_0-\text{C}_2)\text{-alkylene-C(O)-O-(C}_2\text{-C}_4\text{)-alkylene-O-C(O)-O-(C}_1\text{-C}_6\text{)-alkyl}$ ,  
 5 20)  $-\text{C(O)-O-C(R}^{15}, \text{R}^{16}\text{)-O-C(O)-O-R}^{17}$ ,  
 21)  $-(\text{C}_0-\text{C}_4)\text{-alkylene-(C}_6\text{-C}_{14}\text{)-aryl}$ , wherein aryl is as defined above and is mono-, di- or trisubstituted independently of one another by  $\text{R}^{13}$ ,  
 22)  $-(\text{C}_0-\text{C}_4)\text{-alkylene-(C}_4\text{-C}_{15}\text{)-heterocyclyl}$ , wherein the heterocyclyl is unsubstituted or mono-, di- or trisubstituted independently of one another by  $\text{R}^{13}$ ,  
 10 23)  $-(\text{C}_0-\text{C}_4)\text{-alkylene-(C}_3\text{-C}_8\text{)-cycloalkyl}$ , wherein cycloalkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by  $\text{R}^{13}$ ,  
 24)  $-(\text{C}_0-\text{C}_4)\text{-alkylene-het}$ , wherein the het is as defined above and is unsubstituted or mono-, di- or trisubstituted independently of one another by  $\text{R}^{13}$ ,  
 25)  $-(\text{C}_0-\text{C}_3)\text{-alkylene-O-CH}_2\text{-CF}_2\text{-CH}_2\text{-O-(C}_0\text{-C}_3\text{)-alkyl}$ ,  
 15  $-(\text{C}_0-\text{C}_3)\text{-alkylene-O-CH}_2\text{-CF}_2\text{-CF}_2\text{-CH}_2\text{-O-(C}_0\text{-C}_3\text{)-alkyl}$ , or  
 $-(\text{C}_0-\text{C}_3)\text{-alkylene-O-CH}_2\text{-(C}_1\text{-C}_3\text{)-perfluoroalkylene-CH}_2\text{-OH}$ ,  
 26)  $-\text{SO}_w\text{-N(R}^{11}\text{)-R}^{13}$ , wherein w is 1 or 2,  
 27)  $-(\text{C}_0-\text{C}_4)\text{-alkylene-C(O)-N(R}^{11}\text{)-R}^{13}$ ,  
 28)  $-(\text{C}_0-\text{C}_4)\text{-alkylene-N(R}^{11}\text{)-R}^{13}$ , or  
 20 29) a residue selected from the group consisting of





wherein Me is methyl, and two -OR<sup>19</sup> residues and adjacent atoms through which they are attached  
 5 form together with the atoms which they are attached to a 1,3-dioxole ring or a 2,3-dihydro-  
 [1,4]dioxine ring, which is substituted one, two, three or four times by R<sup>13</sup>;

R<sup>11</sup> and R<sup>12</sup> are independently of one another identical or different and are


- 1) hydrogen,
- 10 2) -(C<sub>1</sub>-C<sub>6</sub>)-alkyl, wherein the alkyl is unsubstituted or mono-, di- or trisubstituted  
independently of one another by R<sup>13</sup>,
- 3) -(C<sub>0</sub>-C<sub>6</sub>)-alkyl-(C<sub>6</sub>-C<sub>14</sub>)-aryl, wherein the alkyl and aryl are independently from one  
another unsubstituted or mono-, di- or trisubstituted by R<sup>13</sup>,
- 4) -O-R<sup>17</sup>, or
- 15 5) -(C<sub>0</sub>-C<sub>6</sub>)-alkyl-(C<sub>4</sub>-C<sub>15</sub>)-heterocyclyl, wherein alkyl and heterocyclyl independently  
from one another are unsubstituted or mono-, di- or trisubstituted by R<sup>13</sup>, or

R<sup>11</sup> and R<sup>12</sup> together with the nitrogen atom to which they are bonded form azepine, azetidine, 1,4-  
 diazepane, dioxazole, dioxazine, 1,2-diazepine, 1,3-diazepine, 1,4-diazepine, imidazole,  
 20 imidazoline, imidazolidine, isothiazole, isothiazolidine, isothiazoline, isoxazole, isoxazoline,  
 isoxazolidine, 2-isoxazoline, ketopiperazine, morpholine, [1,4]oxazepane, oxazole,  
 piperazine, piperidine, pyrazine, pyrazole, pyrazoline, pyrazolidine, pyridazine, pyridine,  
 pyrimidine, pyrrole, pyrrolidine, pyrrolidinone, pyrroline, tetrahydropyridine, tetrazine,  
 tetrazole, thiazole, thiadiazole, thiazolidine, thiazoline, thiomorpholine, 1,2,3-triazine, 1,2,4-  
 25 triazine, 1,3,5-triazine, 1,2,3-triazole or 1,2,4-triazole, each of which is unsubstituted or  
 mono-, di- or trisubstituted independently of one another by R<sup>13</sup>;

R<sup>13</sup> is fluorine, chlorine, bromine, iodine, -NO<sub>2</sub>, -CN, =O, -OH, -CF<sub>3</sub>, -C(O)-O-R<sup>10</sup>,  
 -C(O)-N(R<sup>10</sup>)-R<sup>20</sup>, -N(R<sup>10</sup>)-R<sup>20</sup>, -(C<sub>0</sub>-C<sub>3</sub>)-alkylene-O-R<sup>10</sup>, -Si-(CH<sub>3</sub>)<sub>3</sub>,

-N(R<sup>10</sup>)-S(O)<sub>2</sub>-R<sup>10</sup>, -S-R<sup>10</sup>, -SO<sub>2</sub>-R<sup>10</sup>, -S(O)<sub>2</sub>-N(R<sup>10</sup>)-R<sup>20</sup>, -C(O)-R<sup>10</sup>, -(C<sub>1</sub>-C<sub>8</sub>)-alkyl, -(C<sub>1</sub>-C<sub>8</sub>)-alkoxy, phenyl, phenyloxy-, -O-CF<sub>3</sub>, -(C<sub>1</sub>-C<sub>3</sub>)-perfluoroalkyl, -(C<sub>0</sub>-C<sub>4</sub>)-alkyl-C(O)-O-C(R<sup>15</sup>, R<sup>16</sup>)-O-C(O)-R<sup>17</sup>, -(C<sub>1</sub>-C<sub>4</sub>)-alkoxy-phenyl, -(C<sub>0</sub>-C<sub>4</sub>)-alkyl-C(O)-O-C(R<sup>15</sup>, R<sup>16</sup>)-O-C(O)-O-R<sup>17</sup>, -O-R<sup>15</sup>, -NH-C(O)-NH-R<sup>10</sup>, -NH-C(O)-O-R<sup>10</sup>, or a residue selected from the group consisting of

5



10 wherein Me is methyl;

R15 and R16 are independently of one another hydrogen, -(C<sub>1</sub>-C<sub>6</sub>)-alkyl, or together form cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl, wherein each ring is unsubstituted or substituted one to three times by R<sup>10</sup>; and

15

R17 is  $-(C_1-C_6)\text{-alkyl}$ ,  $-(C_1-C_6)\text{-alkyl-OH}$ ,  $-(C_1-C_6)\text{-alkyl-O-(C}_1\text{-C}_6\text{)-alkyl}$ ,  
 $-(C_1-C_6)\text{-alkyl-O-(C}_1\text{-C}_8\text{)-alkyl-(C}_3\text{-C}_8\text{)-cycloalkyl}$ ,  $-(C_1-C_6)\text{-alkyl-(C}_3\text{-C}_8\text{)-cycloalkyl}$ ,  
 wherein the cycloalkyl is unsubstituted or substituted one, two or three times by  $-\text{OH}$ ,  
 $-\text{O-(C}_1\text{-C}_4\text{)-alkyl}$  or  $\text{R}^{10}$ .

20

4. The compound according claim 1, wherein

R0 as 1) is phenyl, wherein phenyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R8, or

3) is pyridyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, pyrrolyl, 2-pyrrolyl, 3-pyrrolyl, furyl, 2-furyl, 3-furyl; thienyl, 2-thienyl, 3-thienyl, imidazolyl, pyrazolyl, oxazolyl, isoxazolyl,

25

thiazolyl, thiadiazolyl, isothiazolyl, triazolyl, tetrazolyl, pyridazinyl or pyrazinyl, each of which is unsubstituted or mono-, di- or trisubstituted independently of one another by R8,

and in addition is substituted by pyridyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, pyrrolyl, 2-pyrrolyl, 3-pyrrolyl, furyl, 2-furyl, 3-furyl; thienyl, 2-thienyl, 3-thienyl, imidazolyl, pyrazolyl, oxazolyl, isoxazolyl, thiazolyl, thiadiazolyl, isothiazolyl, triazolyl, tetrazolyl, pyridazinyl or pyrazinyl, each of which is unsubstituted or mono-, di- or trisubstituted independently of one another by R8;

- R8 is
- 1) F, Cl, Br or I,
  - 4)  $-C(O)-NH_2$ ,
  - 9)  $-(C_1-C_4)$ -alkyl, wherein the alkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by halogen, -OH or methoxy, or
  - 10)  $-O-(C_1-C_4)$ -alkyl, wherein the alkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by halogen or methoxy,
- provided that R8 is at least one halogen,  $-C(O)-NH_2$  or  $-O-(C_1-C_8)$ -alkyl;

substructure D is pyridyl, pyridyl-N-oxide, pyrrolyl, furyl, thienyl, imidazolyl, pyrazolyl, oxazolyl, isoxazolyl, thiazolyl, triazolyl, isothiazolyl, thiadiazolyl, pyrimidinyl, pyridazinyl, or pyrazinyl, and is unsubstituted or substituted 1, 2, 3 or 4 times by R3, or is substituted 1 or 2 times by =O;

Q is a direct bond,  $-C(O)-$ ,  $-SO_2-$  or  $-(C_1-C_6)$ -alkylene,  $-(C_0-C_2)$ -alkylene- $C(O)-NR^{10}$ ;

R<sup>1</sup> is hydrogen,  $-(C_1-C_2)$ -alkyl,  $-(C_1-C_3)$ -alkylene- $C(O)-NH-R^0$ ,  $-(C_1-C_3)$ -perfluoroalkylene,  $-(C_1-C_3)$ -alkylene- $C(O)-O-R^{15}$ ,  $-(C_1-C_3)$ -alkylene- $S(O)_2-(C_1-C_3)$ -alkyl or  $-(C_1-C_3)$ -alkylene- $S(O)_2-N(R^{4'})-R^{5'}$ , wherein R<sup>4'</sup> and R<sup>5'</sup> independently of one another are hydrogen atom or  $-(C_1-C_4)$ -alkyl,

R<sup>2</sup> is a direct bond or  $-(C_1-C_2)$ -alkylene, or

R<sup>1</sup>-N-R<sup>2</sup>-V form azetidine, azetidinone, piperidine, piperazine, pyridine, pyrimidine, pyrrolidine, pyrrolidinone, 1,2,3-triazine, 1,2,4-triazine, 1,3,5-triazine, 1,2,3-triazole, 1,2,4-triazole, tetrazine, tetrazole, 1,4-diazepane, 1,2-diazepine, 1,3-diazepine, 1,4-diazepine, azepine, ketopiperazine, 1,4-oxazepane, oxazole, isoxazole, isoxazolidine, 2-isoxazoline, morpholine,

thiazole, isothiazole, thiadiazole or thiomorpholine, each of which is unsubstituted or mono-, di- or trisubstituted independently of one another by R14;

R14 is fluorine, chlorine, -OH, =O, -(C<sub>1</sub>-C<sub>8</sub>)-alkyl, -C(O)-OH, -CN, -NH<sub>2</sub>, -C(O)-O-(C<sub>1</sub>-C<sub>4</sub>)-alkyl,  
 5 -C(O)-NH-(C<sub>1</sub>-C<sub>8</sub>)-alkyl, -C(O)-N-[(C<sub>1</sub>-C<sub>8</sub>)-alkyl]<sub>2</sub>, -C(O)-NH<sub>2</sub> or -N(R<sup>18</sup>)-R<sup>21</sup>,  
 wherein R<sup>18</sup> and R<sup>21</sup> are independently from each other hydrogen, -(C<sub>1</sub>-C<sub>3</sub>)-perfluoroalkyl  
 or -(C<sub>1</sub>-C<sub>4</sub>)-alkyl;

V is 2) phenyl, wherein the phenyl is unsubstituted or mono-, di- or trisubstituted  
 10 independently of one another by R14, or  
 3) azaindole (1H-pyrrolopyridine), aziridine, azirine, azetidine, azetidinone, 1,4-diazepane, pyrrole, pyrrolidine, pyridonyl, imidazole, pyrazole, 1,2,3-triazole, 1,2,4-triazole, tetrazole, pyridine, pyrimidine, pyrazine, 1,2,3-triazine, 1,2,4-triazine, 1,3,5-triazine, tetrazine, tetrazole, azepine, diazirine, 1,2-diazepine, 1,3-diazepine, 1,4-diazepine, pyridazine,  
 15 piperidine, piperazine, pyrrolidinone, ketopiperazine, furan, pyran, dioxole, 1,4-oxazepane, oxazole, isoxazole, 2-isoxazoline, isoxazolidine, morpholine, oxirane, oxaziridine, 1,3-dioxolene, 1,3-dioxolane, 1,2-oxazine, 1,3-oxazine, 1,4-oxazine, oxaziridine, thiophene, thiopyran, thietan, thiazole, isothiazole, isothiazoline, isothiazolidine, 1,2-oxathiolan, thiodiazole, thiopyran, 1,2-thiazine, 1,3-thiazole, 1,3-thiazine, 1,4-thiazine, thiadiazine or  
 20 thiomorpholine, each of which is unsubstituted or mono-, di- or trisubstituted independently of one another by R14;

G is a direct bond, -(CH<sub>2</sub>)<sub>m</sub>-, or -(CH<sub>2</sub>)<sub>m</sub>-NR<sup>10</sup>-;

25 m is zero, 1, 2, 3 or 4;

M is 1) hydrogen,  
 2) -(C<sub>1</sub>-C<sub>6</sub>)-alkyl, wherein the alkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R14,  
 30 3) -C(O)-N(R<sup>11</sup>)-R<sup>12</sup>, or  
 6) heterocyclyl, wherein the heterocyclyl is selected from the group consisting of azepane, azepine, 1,4-diazepane, 1,2-diazepine, 1,3-diazepine, 1,4-diazepine, imidazole, isothiazole, isoxazole, isoxazolidine, 2-isoxazoline, ketomorpholine, ketopiperazine, morpholine, oxazole, [1,4]-oxazepane, piperazine, piperazinone, piperidine, piperidinone,  
 35 pyrazine, pyridazine, pyridazinone, pyridine, pyridone, pyrimidine, pyrrolidine,

pyrrolidinone, tetrahydropyran, 1,4,5,6-tetrahydro-pyridazinyl, tetrazine, tetrazole, thiadiazole, thiazole, thiomorpholine, thiophene, 1,2,3-triazine, 1,2,4-triazine, 1,3,5-triazine, 1,2,3-triazole or 1,2,4-triazole, each of which is unsubstituted or mono-, di- or trisubstituted independently of one another by R14, or


5 7) (C<sub>3</sub>-C<sub>6</sub>)-cycloalkyl;

R3 is

- 1) hydrogen,
- 2) halogen,
- 10 3) -(C<sub>1</sub>-C<sub>4</sub>)-alkyl, wherein the alkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R13,
- 4) -(C<sub>1</sub>-C<sub>3</sub>)-perfluoroalkyl,
- 5) phenyl, wherein the phenyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R13,
- 15 6) -(C<sub>0</sub>-C<sub>4</sub>)-alkylene-O-R19,
- 8) -CN,
- 8) -NR<sup>10</sup>-SO<sub>2</sub>-R<sup>10</sup>,
- 9) -SO<sub>s</sub>-R<sup>11</sup>, wherein s is 1 or 2,
- 10) -SO<sub>t</sub>-N(R<sup>11</sup>)-R<sup>12</sup>, wherein t is 1 or 2,
- 20 11) -(C<sub>0</sub>-C<sub>4</sub>)-alkylene-C(O)-R<sup>11</sup>,
- 12) -(C<sub>0</sub>-C<sub>4</sub>)-alkylene-C(O)-O-R<sup>11</sup>,
- 13) -(C<sub>0</sub>-C<sub>4</sub>)-alkylene-C(O)-N(R<sup>11</sup>)-R<sup>12</sup>,
- 14) -(C<sub>0</sub>-C<sub>4</sub>)-alkylene-N(R<sup>11</sup>)-R<sup>12</sup>,
- 17) -(C<sub>0</sub>-C<sub>2</sub>)-alkylene-C(O)-O-(C<sub>2</sub>-C<sub>4</sub>)-alkylene-O-C(O)-(C<sub>1</sub>-C<sub>4</sub>)-alkyl,
- 25 18) -C(O)-O-C(R15, R16)-O-C(O)-R17,
- 19) -(C<sub>0</sub>-C<sub>2</sub>)-alkylene-C(O)-O-(C<sub>2</sub>-C<sub>4</sub>)-alkylene-O-C(O)-O-(C<sub>1</sub>-C<sub>6</sub>)-alkyl,
- 20) -C(O)-O-C(R15, R16)-O-C(O)-O-R17,
- 25) -(C<sub>0</sub>-C<sub>3</sub>)-alkylene-O-CH<sub>2</sub>-CF<sub>2</sub>-CH<sub>2</sub>-O-(C<sub>0</sub>-C<sub>3</sub>)-alkyl,
- (C<sub>0</sub>-C<sub>3</sub>)-alkylene-O-CH<sub>2</sub>-CF<sub>2</sub>-CF<sub>2</sub>-CH<sub>2</sub>-O-(C<sub>0</sub>-C<sub>3</sub>)-alkyl, or
- 30 -(C<sub>0</sub>-C<sub>3</sub>)-alkylene-O-CH<sub>2</sub>-(C<sub>1</sub>-C<sub>3</sub>)-perfluoroalkylene-CH<sub>2</sub>-OH,
- 26) -SO<sub>w</sub>-N(R<sup>11</sup>)-R<sup>13</sup>, wherein w is 1 or 2,
- 27) -(C<sub>0</sub>-C<sub>4</sub>)-alkylene-C(O)-N(R<sup>11</sup>)-R<sup>13</sup>,

28)  $-(C_0-C_4)\text{-alkylene-N(R}^{11})\text{-R}^{13}$ , or

29) a residue selected from the group consisting of



5 wherein Me is methyl;

two -OR<sup>19</sup> residues and adjacent atoms through which they are attached may form together a 1,3-dioxole ring or a 2,3-dihydro-[1,4]dioxine ring, each of which is substituted one, two, three or four times by R<sup>13</sup>;


10

R<sup>11</sup> and R<sup>12</sup> together with the nitrogen atom to which they are bonded form azepine, azetidine, 1,4-diazepane, dioxazole, dioxazine, 1,2-diazepine, 1,3-diazepine, 1,4-diazepine, imidazole, imidazoline, imidazolidine, isothiazole, isothiazolidine, isothiazoline, isoxazole, isoxazoline, isoxazolidine, 2-isoxazoline, ketopiperazine, morpholine, [1,4]-oxazepane, oxazole, piperazine, piperidine, pyrazine, pyrazole, pyrazoline, pyrazolidine, pyridazine, pyridine, pyrimidine, pyrrole, pyrrolidine, pyrrolidinone, pyrroline, tetrahydropyridine, tetrazine, tetrazole, thiazole, thiadiazole, thiazolidine, thiazoline, thiomorpholine, thiophene, 1,2,3-triazine, 1,2,4-triazine, 1,3,5-triazine, 1,2,3-triazole or 1,2,4-triazole, each of which is unsubstituted or mono-, di- or trisubstituted independently of one another by R<sup>13</sup>;

20

R<sup>13</sup> is fluorine, chlorine, -NO<sub>2</sub>, -CN, =O, -OH, -CF<sub>3</sub>, -C(O)-O-R<sup>10</sup>, -C(O)-N(R<sup>10</sup>)-R<sup>20</sup>, -N(R<sup>10</sup>)-R<sup>20</sup>, -(C<sub>0</sub>-C<sub>3</sub>)-alkylene-O-R<sup>10</sup>, -Si-(CH<sub>3</sub>)<sub>3</sub>, -N(R<sup>10</sup>)-S(O)<sub>2</sub>-R<sup>10</sup>, -S-R<sup>10</sup>, -SO<sub>2</sub>-R<sup>10</sup>, -S(O)<sub>2</sub>-N(R<sup>10</sup>)-R<sup>20</sup>, -C(O)-R<sup>10</sup>, -(C<sub>1</sub>-C<sub>8</sub>)-alkyl, -(C<sub>1</sub>-C<sub>8</sub>)-alkoxy, phenyl, phenyloxy-, -O-CF<sub>3</sub>, -(C<sub>1</sub>-C<sub>3</sub>)-perfluoroalkyl, -NH-C(O)-NH-R<sup>10</sup>, -(C<sub>0</sub>-C<sub>4</sub>)-alkyl-C(O)-O-C(R<sup>15</sup>, R<sup>16</sup>)-O-C(O)-R<sup>17</sup>, -(C<sub>1</sub>-C<sub>4</sub>)-alkoxy-phenyl, -(C<sub>0</sub>-C<sub>4</sub>)-alkyl-C(O)-O-C(R<sup>15</sup>, R<sup>16</sup>)-O-C(O)-O-R<sup>17</sup>, -O-R<sup>15</sup>, -NH-C(O)-O-R<sup>10</sup>, or a residue selected from the group consisting of

25



wherein Me is methyl;

- 5 R15 and R16 are independently of one another hydrogen,  $-(\text{C}_1\text{-C}_6)\text{-alkyl}$ , or together form cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl, wherein each ring is unsubstituted or substituted one to three times by  $\text{R}^{10}$ ; and

- R17 is  $-(\text{C}_1\text{-C}_6)\text{-alkyl}$ ,  $-(\text{C}_1\text{-C}_6)\text{-alkyl-OH}$ ,  $-(\text{C}_1\text{-C}_6)\text{-alkyl-O}-(\text{C}_1\text{-C}_6)\text{-alkyl}$ ,  
 10  $-(\text{C}_1\text{-C}_6)\text{-alkyl-O}-(\text{C}_1\text{-C}_8)\text{-alkyl}-(\text{C}_3\text{-C}_8)\text{-cycloalkyl}$ ,  $-(\text{C}_0\text{-C}_6)\text{-alkyl}-(\text{C}_3\text{-C}_8)\text{-cycloalkyl}$ ,  
 wherein the cycloalkyl is unsubstituted or substituted one, two or three times by  $-\text{OH}$ ,  
 $-\text{O}-(\text{C}_1\text{-C}_4)\text{-alkyl}$  or  $\text{R}^{10}$ .

5. The compound according to claim 1, wherein

- 15 R0 is 1) phenyl, wherein the phenyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R8,  
 2) indolyl, isoindolyl, benzofuranyl, benzothiophenyl, 1,3-benzodioxolyl, indazolyl, benzimidazolyl, benzoxazolyl, benzothiazolyl, quinoliny, isoquinoliny, chromanyl, isochromanyl, cinnoliny, quinazoliny, quinoxaliny, phthalaziny, pyridoimidazolyl,  
 20 pyridopyridiny, pyridopyrimidiny, pyridyl, puriny or pteridiny, each of which is unsubstituted or mono-, di- or trisubstituted independently of one another by R8,  
 3) pyridyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, pyrrolyl, 2-pyrrolyl, 3-pyrrolyl, furyl, 2-furyl, 3-furyl; thienyl, 2-thienyl, 3-thienyl, imidazolyl, pyrazolyl, oxazolyl, isoxazolyl, thiazolyl, thiadiazolyl, isothiazolyl, triazolyl, tetrazolyl, pyridaziny or pyraziny, each of which is  
 25 unsubstituted or mono-, di- or trisubstituted independently of one another by R8, and in addition is substituted by pyridyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, pyrrolyl, 2-pyrrolyl, 3-pyrrolyl, furyl, 2-furyl, 3-furyl; thienyl, 2-thienyl, 3-thienyl, imidazolyl, pyrazolyl, oxazolyl, isoxazolyl, thiazolyl, thiadiazolyl, isothiazolyl, triazolyl, tetrazolyl, pyridaziny and pyraziny, each of which is unsubstituted or mono-, di- or trisubstituted independently of one another by R8;  
 30



R8 is 1) F, Cl, Br, or I,  
 4) -C(O)-NH<sub>2</sub>,  
 9) -(C<sub>1</sub>-C<sub>4</sub>)-alkyl, wherein the alkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by halogen, -OH or methoxy, or  
 5 10) -O-(C<sub>1</sub>-C<sub>4</sub>)-alkyl, wherein the alkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by halogen or methoxy,  
 provided that R8 is at least one halogen, -C(O)-NH<sub>2</sub> or -O-(C<sub>1</sub>-C<sub>8</sub>)-alkyl residue;

substructure D is pyridyl, pyridyl-N-oxide, pyrrolyl, furyl, thienyl, imidazolyl, pyrazolyl, oxazolyl,  
 10 isoxazolyl, thiazolyl, triazolyl, isothiazolyl, thiadiazolyl, pyrimidinyl, pyridazinyl, or  
 pyrazinyl, and is unsubstituted or substituted 1, 2, 3 or 4 times by R<sup>3</sup>, or is substituted 1 or 2  
 times by =O;

Q is a direct bond, -C(O)-, -SO<sub>2</sub>-, -(C<sub>1</sub>-C<sub>6</sub>)-alkylene or -(C<sub>0</sub>-C<sub>2</sub>)-alkylene-C(O)-NR<sup>10</sup>;  
 15

R<sup>1</sup> is hydrogen or -(C<sub>1</sub>-C<sub>2</sub>)-alkyl,

R<sup>2</sup> is a direct bond or -(C<sub>1</sub>-C<sub>2</sub>)-alkylene, or

20 R<sup>1</sup>-N-R<sup>2</sup>-V form piperidine, piperazine, pyridine, pyrimidine, pyrrolidine, pyrrolidinone, 1,2,3-  
 triazine, 1,2,4-triazine, 1,3,5-triazine, 1,2,3-triazole, 1,2,4-triazole, tetrazine, tetrazole, 1,2-  
 diazepine, 1,3-diazepine, 1,4-diazepine, azepine, ketopiperazine, oxazole, isoxazole,  
 isoxazolidine, 2-isoxazoline, morpholine, thiazole, isothiazole, thiadiazole or thiomorpholine,  
 each of which is unsubstituted or mono-, di- or trisubstituted independently of one another by  
 25 R<sup>14</sup>;

R<sup>14</sup> is fluorine, chlorine, =O, -(C<sub>1</sub>-C<sub>4</sub>)-alkyl or -NH<sub>2</sub>;

V is 2) phenyl, wherein the phenyl is unsubstituted or mono-, di- or trisubstituted  
 30 independently of one another by R<sup>14</sup>, or  
 3) azaindolyl (1H-pyrrolopyridyl), azetidine, azepine, aziridine, azirine, 1,4-diazepane,  
 1,2-diazepine, 1,3-diazepine, 1,4-diazepine, diazirine, 1,3-dioxolane, dioxazole, furan,  
 imidazole, isoquinoline, isothiazole, isothiazolidine, isothiazoline, isoxazole, 2-isoxazoline,  
 isoxazolidine, ketopiperazine, morpholine, 1,2-oxazine, 1,3-oxazine, 1,4-oxazine, oxazole,  
 35 1,2-oxathiolan, piperidine, pyran, pyrazine, pyrazole, pyridazine, piperazine, pyridine,  
 pyridone, pyrimidine, pyrrole, pyrrolidine, pyrrolidinone, quinazoline, quinoline, tetrazine,

tetrazole, thiadiazine, 1,2-thiazine, 1,3-thiazine, 1,4-thiazine, 1,3-thiazole, thietan, thiomorpholine, thiophene, thiopyran, 1,2,3-triazine, 1,2,4-triazine, 1,3,5-triazine, 1,2,3-triazole or 1,2,4-triazole, each of which is unsubstituted or mono-, di- or trisubstituted independently of one another by R14;

5

G is a direct bond,  $-(CH_2)_m-$ , or  $-(CH_2)_m-NR^{10}-$ ;

m is zero, 1, 2, 3 or 4;

10

M is

- 1) hydrogen,
- 2)  $-(C_1-C_6)$ -alkyl, wherein the alkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R14,
- 6) heterocyclyl, wherein the heterocyclyl is selected from the group consisting of 1,4-diazepane, ketomorpholine, thiophene, pyridazone, piperidine, piperazine, pyridine,
- 15) pyrimidine, pyrrolidine, pyrrolidinone, pyridonyl, imidazole, pyridazine, pyrazine, 1,2,3-triazine, 1,2,4-triazine, 1,3,5-triazine, 1,2,3-triazole, 1,2,4-triazole, tetrazine, tetrazole, 1,2-diazepine, 1,3-diazepine, 1,4-diazepine, azepine, ketopiperazine, oxazole, isoxazole, isoxazolidine, 2-isoxazoline, morpholine, thiazole, isothiazole, tetrahydropyran, 1,4,5,6-tetrahydro-pyridazinyl, thiadiazole or thiomorpholine, each of which is unsubstituted or
- 20) mono-, di- or trisubstituted independently of one another by R14, or
- 7)  $(C_3-C_6)$ -cycloalkyl;

R3 is

- 1) hydrogen,

2) halogen,

25

3)  $-(C_1-C_4)$ -alkyl, wherein the alkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R13,

4)  $-(C_1-C_3)$ -perfluoroalkyl,

5) phenyl, wherein the phenyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R13,

30

6)  $-(C_0-C_4)$ -alkylene-O-R19,


8) -CN,

9)  $-SO_s-R^{11}$ , wherein s is 1 or 2,

10)  $-SO_t-N(R^{11})-R^{12}$ , wherein t is 1 or 2,

11)  $-(C_0-C_4)$ -alkylene-C(O)-R<sup>11</sup>,

- 12)  $-(C_0-C_4)\text{-alkylene-C(O)-O-R}^{11}$ ,
- 13)  $-(C_0-C_4)\text{-alkylene-C(O)-N(R}^{11})\text{-R}^{12}$ ,
- 14)  $-(C_0-C_4)\text{-alkylene-N(R}^{11})\text{-R}^{12}$ ,
- 15)  $-\text{NR}^{10}\text{-SO}_2\text{-R}^{10}$ ,
- 5 17)  $-(C_0-C_2)\text{alkylene-C(O)-O-(C}_2\text{-C}_4\text{)-alkylene-O-C(O)-(C}_1\text{-C}_4\text{)-alkyl}$ ,
- 18)  $-\text{C(O)-O-C(R}^{15}, \text{R}^{16})\text{-O-C(O)-R}^{17}$ ,
- 19)  $-(C_0-C_2)\text{alkylene-C(O)-O-(C}_2\text{-C}_4\text{)-alkylene-O-C(O)-O-(C}_1\text{-C}_6\text{)-alkyl}$ ,
- 20)  $-\text{C(O)-O-C(R}^{15}, \text{R}^{16})\text{-O-C(O)-O-R}^{17}$ , or
- 29) a residue selected from the group consisting of




wherein Me is methyl;

- 15 R19 is a) hydrogen,  
b)  $-(C_1-C_4)$ -alkyl, wherein the alkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R13,  
c)  $-CF_3$ , or  
d)  $-CHF_2$ ;
- 20 R11 and R12 are independently of one another identical or different and are  
1) hydrogen,  
2)  $-(C_1-C_4)$ -alkyl, wherein the alkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R13,  
3)  $-(C_0-C_6)$ -alkyl- $(C_3-C_6)$ -cycloalkyl,
- 25 7)  $-O-R^{17}$ , or  
8)  $-(C_0-C_6)$ -alkyl- $(C_4-C_{15})$ -heterocyclyl, wherein the alkyl and heterocyclyl independently from one another are unsubstituted or mono-, di- or trisubstituted by R13 and wherein the heterocyclyl is azetidine, cyclopropyl, cyclobutyl, 4,5-dihydro-oxazole, imidazolidine,

morpholine, (1,4)-oxazepane, oxazolidine, piperidine, piperazine, pyrrolidine, tetrahydrothiophene, thiazolidine or thiomorpholine, or

R11 and R12 together with the nitrogen atom to which they are bonded form azetidine, cyclopropyl, cyclobutyl, 4,5-dihydro-oxazole, imidazolidine, morpholine, (1,4)-oxazepane, oxazolidine, piperidine, piperazine, pyrrolidine, tetrahydrothiophene, thiazolidine or thiomorpholine;

R13 is fluorine, -CN, =O, -OH, -CF<sub>3</sub>, -C(O)-O-R<sup>10</sup>, -C(O)-N(R<sup>10</sup>)-R<sup>20</sup>, -N(R<sup>10</sup>)-R<sup>20</sup>, -(C<sub>3</sub>-C<sub>6</sub>)-cycloalkyl, -(C<sub>0</sub>-C<sub>3</sub>)-alkylene-O-R<sup>10</sup>, -Si-(CH<sub>3</sub>)<sub>3</sub>, -S-R<sup>10</sup>, -SO<sub>2</sub>-R<sup>10</sup>, -(C<sub>1</sub>-C<sub>3</sub>)-perfluoroalkyl, or a residue selected from the group consisting of



wherein Me is methyl;

R<sup>10</sup> and R<sup>20</sup> are independently of one another hydrogen, -(C<sub>1</sub>-C<sub>4</sub>)-alkyl or -(C<sub>1</sub>-C<sub>3</sub>)-perfluoroalkyl;

R<sup>15</sup> and R<sup>16</sup> are independently of one another hydrogen, -(C<sub>1</sub>-C<sub>4</sub>)-alkyl, or together form cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl, wherein each ring is unsubstituted or substituted one to three times by R<sup>10</sup>, and

R17 is -(C<sub>1</sub>-C<sub>6</sub>)-alkyl, -(C<sub>1</sub>-C<sub>6</sub>)-alkyl-OH, -(C<sub>1</sub>-C<sub>6</sub>)-alkyl-O-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, -(C<sub>1</sub>-C<sub>6</sub>)-alkyl-O-(C<sub>1</sub>-C<sub>8</sub>)-alkyl-(C<sub>3</sub>-C<sub>8</sub>)-cycloalkyl, -(C<sub>0</sub>-C<sub>6</sub>)-alkyl-(C<sub>3</sub>-C<sub>8</sub>)-cycloalkyl, wherein the cycloalkyl is unsubstituted or substituted one, two or three times by -OH, -O-(C<sub>1</sub>-C<sub>4</sub>)-alkyl or R<sup>10</sup>.

6. The compound according to claim 1, wherein

R0 is 1) phenyl, wherein the phenyl is unsubstituted or mono- or disubstituted independently of one another by R8,

- 2) pyridyl or benzothiophenyl, wherein the pyridyl and benzothiophenyl are unsubstituted or mono- or disubstituted independently of one another by R8, or
- 3) thienyl, thiadiazolyl, isoxazolyl or thiazolyl, each of which is substituted by thienyl, 2-thienyl or 3-thienyl, wherein the thienyl, 2-thienyl or 3-thienyl is unsubstituted or mono- or disubstituted independently of one another by R8;

R8 is F, Cl, Br, -OCH<sub>3</sub> or -C(O)-NH<sub>2</sub>;

- substructure D is pyridyl, pyridyl-N-oxide, pyrrolyl, thienyl, imidazolyl, pyrazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, thiadiazolyl, pyrimidinyl, pyridazinyl or pyrazinyl, and is unsubstituted or substituted 1, 2, 3 or 4 times by R3, or is substituted 1 or 2 times by =O;

Q is a direct bond, -C(O)-, -SO<sub>2</sub>-, -CH<sub>2</sub>-C(O)-NH-, methylene or ethylene;

- R<sup>1</sup> is hydrogen,

,

R<sup>2</sup> is a direct bond or methylene, or

R<sup>1</sup>-N-R<sup>2</sup>-V form azetidine, pyrrolidine, piperidine and piperazine;

R14 is fluorine, chlorine, =O, methyl, ethyl or -NH<sub>2</sub>;

V is 2) phenyl, wherein the phenyl is unsubstituted or mono- or disubstituted independently of one another by R14 or

- 3) azaindolyl (1H-pyrrolopyridyl), azetidine, 1,4-diazepane, isoxazole, isoquinoline, piperazine, piperidine, pyrazine, pyridazine, pyrimidine, pyrrolidine, quinazoline, quinoline or tetrahydropyran, each of which is unsubstituted or mono- or disubstituted independently of one another by R14;

- G is a direct bond, -(CH<sub>2</sub>)<sub>m</sub>-, or -(CH<sub>2</sub>)<sub>m</sub>-NR<sup>10</sup>-;

m is zero, 1 or 2;

M is 1) hydrogen,

- 2) (C<sub>2</sub>-C<sub>4</sub>)-alkyl, wherein the alkyl is unsubstituted or mono- or disubstituted independently of one another by R<sub>14</sub>, or
- 6) azepanyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, imidazolyl, ketomorpholiny, morpholiny, [1,4]Oxazepanyl, piperidiny, piperidonyl, pyraziny, pyrazolyl, pyridaziny, pyridyl, pyrimidyl, pyrrolidiny, 1,4,5,6-tetrahydro-pyridaziny, or tetrahydropyrany, each of which is unsubstituted or mono- or disubstituted independently of one another by R<sub>14</sub>;

R<sub>3</sub> is

- 1) hydrogen,
- 2) F or Cl,,
- 3) -(C<sub>1</sub>-C<sub>4</sub>)-alkyl, wherein alkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R<sub>13</sub>,
- 4) -(C<sub>1</sub>-C<sub>3</sub>)-perfluoroalkyl,
- 5) phenyl, wherein the phenyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R<sub>13</sub>,
- 6) -(C<sub>0</sub>-C<sub>2</sub>)-alkylene-O-R<sub>19</sub>,
- 8) -CN,
- 9) -SO<sub>s</sub>-R<sup>11</sup>, wherein s is 1 or 2,
- 10) -SO<sub>t</sub>-N(R<sup>11</sup>)-R<sup>12</sup>, wherein t is 1 or 2,
- 11) -(C<sub>0</sub>-C<sub>4</sub>)-alkylene-C(O)-R<sup>11</sup>,
- 12) -(C<sub>0</sub>-C<sub>4</sub>)-alkylene-C(O)-O-R<sup>11</sup>,
- 13) -(C<sub>0</sub>-C<sub>4</sub>)-alkylene-C(O)-N(R<sup>11</sup>)-R<sup>12</sup>,
- 14) -(C<sub>0</sub>-C<sub>4</sub>)-alkylene-N(R<sup>11</sup>)-R<sup>12</sup>,
- 15) -NR<sup>10</sup>-SO<sub>2</sub>-R<sup>10</sup>,
- 17) -(C<sub>0</sub>-C<sub>2</sub>)alkylene-C(O)-O-(C<sub>2</sub>-C<sub>4</sub>)-alkylene-O-C(O)-(C<sub>1</sub>-C<sub>4</sub>)-alkyl,
- 18) -C(O)-O-C(R<sub>15</sub>, R<sub>16</sub>)-O-C(O)-R<sub>17</sub>,
- 19) -(C<sub>0</sub>-C<sub>2</sub>)alkylene-C(O)-O-(C<sub>2</sub>-C<sub>4</sub>)-alkylene-O-C(O)-O-(C<sub>1</sub>-C<sub>6</sub>)-alkyl or
- 20) -C(O)-O- C(R<sub>15</sub>, R<sub>16</sub>)-O-C(O)-O-R<sub>17</sub>;

- R<sub>19</sub> is a) hydrogen,
- b) -(C<sub>1</sub>-C<sub>4</sub>)-alkyl, wherein the alkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R<sub>13</sub>, or

- c)  $-\text{CF}_3$ , or
- d)  $-\text{CHF}_2$ ;

R11 and R12 are independently of one another identical or different and are

- 5           1) hydrogen,
- 2)  $-(\text{C}_1\text{-C}_4)\text{-alkyl}$ , wherein the alkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R13,
- 3)  $-(\text{C}_0\text{-C}_6)\text{-alkyl-(C}_3\text{-C}_6)\text{-cycloalkyl}$ ,
- 7)  $-\text{O-R}^{17}$ , or
- 10          8)  $-(\text{C}_0\text{-C}_6)\text{-alkyl-heterocyclyl}$ , wherein the alkyl and heterocyclyl independently from one another are unsubstituted or mono-, di- or trisubstituted by R13 and wherein the heterocyclyl is azetidine, imidazolidine, morpholine, (1,4)-oxazepane or pyrrolidine, or

- 15       R11 and R12 together with the nitrogen atom to which they are bonded form azetidine, imidazolidine, morpholine, (1,4)-oxazepane piperazine, piperidine, pyrrolidine or thiomorpholine;

R13 is fluorine,  $-\text{CN}$ ,  $=\text{O}$ ,  $-\text{OH}$ ,  $-\text{CF}_3$ ,  $-\text{C}(\text{O})\text{-O-R}^{10}$ ,  $-\text{C}(\text{O})\text{-N(R}^{10})\text{-R}^{20}$ ,  $-\text{N(R}^{10})\text{-R}^{20}$ ,  
 $-(\text{C}_3\text{-C}_6)\text{-cycloalkyl}$ ,  $-(\text{C}_0\text{-C}_3)\text{-alkylene-O-R}^{10}$ ,  $-\text{Si}(\text{CH}_3)_3$ ,  $-\text{S-R}^{10}$ ,  $-\text{SO}_2\text{-R}^{10}$ , or  
 20        $-(\text{C}_1\text{-C}_3)\text{-perfluoroalkyl}$ ;

$\text{R}^{10}$  and  $\text{R}^{20}$  are independently of one another hydrogen,  $-(\text{C}_1\text{-C}_4)\text{-alkyl}$  or  $-(\text{C}_1\text{-C}_3)\text{-perfluoroalkyl}$ ;

- 25        $\text{R}^{15}$  and  $\text{R}^{16}$  are independently of one another hydrogen,  $-(\text{C}_1\text{-C}_4)\text{-alkyl}$ , or together form cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl, wherein each ring is unsubstituted or substituted one to three times by  $\text{R}^{10}$ ; and

- 30       R17 is  $-(\text{C}_1\text{-C}_6)\text{-alkyl}$ ,  $-(\text{C}_1\text{-C}_6)\text{-alkyl-OH}$ ,  $-(\text{C}_1\text{-C}_6)\text{-alkyl-O-(C}_1\text{-C}_6)\text{-alkyl}$ ,  
 $-(\text{C}_1\text{-C}_6)\text{-alkyl-O-(C}_1\text{-C}_8)\text{-alkyl-(C}_3\text{-C}_8)\text{-cycloalkyl}$ ,  $-(\text{C}_0\text{-C}_6)\text{-alkyl-(C}_3\text{-C}_8)\text{-cycloalkyl}$ ,  
 wherein the cycloalkyl is unsubstituted or substituted one, two or three times by  $-\text{OH}$ ,  
 $-\text{O-(C}_1\text{-C}_4)\text{-alkyl}$  or  $\text{R}^{10}$ .

- 7.       The compound according to claim 1, wherein

- R0 is 1) pyridyl or benzothiophenyl, wherein the pyridyl and benzothiophenyl are unsubstituted or mono- or disubstituted independently of one another by R8, or  
 2) thienyl, thiadiazolyl, isoxazolyl and thiazolyl, each of which is substituted by thienyl, 2-thienyl and 3-thienyl, wherein the thienyl, 2-thienyl or 3-thienyl is unsubstituted or mono-  
 5 or disubstituted independently of one another by R8;
- R8 is F, Cl, Br, -OCH<sub>3</sub> or -C(O)-NH<sub>2</sub>;
- substructure D is pyridyl and is unsubstituted or substituted 1, 2, 3 or 4 times by R3, or is substituted  
 10 1 or 2 times by =O;
- Q is -CH<sub>2</sub>-C(O)-NH- or methylene;
- R<sup>1</sup> is hydrogen atom;
- 15 R<sup>2</sup> is a direct bond;
- R14 is fluorine, chlorine, =O, methyl, ethyl or -NH<sub>2</sub>;
- V is piperidine, wherein the piperidine is unsubstituted or mono- or disubstituted independently of  
 20 one another by R14;
- G is a direct bond;
- M is hydrogen, (C<sub>2</sub>-C<sub>4</sub>)-alkyl, or pyridyl, wherein the alkyl or pyridyl is unsubstituted or mono- or  
 25 disubstituted independently of one another by R14;
- R3 is 1) hydrogen,  
 2) fluorine, or chlorine,  
 3) -(C<sub>1</sub>-C<sub>4</sub>)-alkyl, wherein the alkyl is unsubstituted or mono-, di- or trisubstituted  
 30 independently of one another by R13,  
 6) -(C<sub>0</sub>-C<sub>2</sub>)-alkylene-O-R<sup>19</sup>,  
 12) -(C<sub>0</sub>-C<sub>4</sub>)-alkylene-C(O)-O-R<sup>11</sup> or  
 13) -(C<sub>0</sub>-C<sub>4</sub>)-alkylene-C(O)-N(R<sup>11</sup>)-R<sup>12</sup>;
- 35 R<sup>19</sup> is



- a) hydrogen or
- b)  $-(C_1-C_4)$ -alkyl, wherein the alkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R13;

5 R11 and R12 are independently of one another identical or different and are

- 1) hydrogen or
- 2)  $-(C_1-C_4)$ -alkyl, wherein the alkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R13, or

10 R11 and R12 together with the nitrogen atom to which they are bonded form azetidine, imidazolidine, morpholine, (1,4)-oxazepane piperazine, piperidine, pyrrolidine or thiomorpholine;

R13 is fluorine, =O, -OH, -CF<sub>3</sub>, -C(O)-O-R<sup>10</sup>, -C(O)-N(R<sup>10</sup>)-R<sup>20</sup>, -N(R<sup>10</sup>)-R<sup>20</sup>, or  
 $-(C_0-C_3)$ -alkylene-O-R<sup>10</sup>; and

15


R<sup>10</sup> and R<sup>20</sup> are independently of one another hydrogen,  $-(C_1-C_4)$ -alkyl or  $-(C_1-C_3)$ -perfluoroalkyl.

8. The compound according to claim 1, wherein the compound is

- 1-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-1H-pyrrolo[2,3-b]pyridine-2- carboxylic acid (1-isopropyl-piperidin-4-yl)-amide,
- 1-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-2-(1-isopropyl-piperidin-4-ylcarbamoyl)-1H-pyrrolo[2,3-b]pyridine-5-carboxylic acid methyl ester,
- 1-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-2-(1-isopropyl-piperidin-4-ylcarbamoyl)-1H-pyrrolo[2,3-b]pyridine-5-carboxylic acid,
- 25 1-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-1H-pyrrolo[2,3-b]pyridine-2,5-dicarboxylic acid 5-amide 2-[(1-isopropyl-piperidin-4-yl)-amide],
- 1-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-1H-pyrrolo[3,2-b]pyridine-2- carboxylic acid (1-isopropyl-piperidin-4-yl)-amide ,
- 1-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-2-(1-isopropyl-piperidin-4-ylcarbamoyl)-1H-pyrrolo[3,2-b]pyridine-5-carboxylic acid ,
- 30 1-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-5-oxo-4,5-dihydro-1H-pyrrolo[3,2-b]pyridine-2-carboxylic acid (1-isopropyl-piperidin-4-yl)-amide ,
- 1-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-2-(3,4,5,6-tetrahydro-2H-[1,4']bipyridinyl-4-ylcarbamoyl)-1H-pyrrolo[3,2-b]pyridine-5-carboxylic acid methyl ester,

- 1-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-2-(3,4,5,6-tetrahydro-2H-[1,4']bipyridinyl-4-ylcarbamoyl)-1H-pyrrolo[3,2-b]pyridine-5-carboxylic acid ,  
 1-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-5-(2-methoxy-ethoxy)-1H-pyrrolo[2,3-c]pyridine-2-carboxylic acid (1-isopropyl-piperidin-4-yl)-amide,  
 1-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-5-(2-hydroxy-ethoxy)-1H-pyrrolo[2,3-c]pyridine-2-carboxylic acid (1-isopropyl-piperidin-4-yl)-amide ,  
 1-[(5-Chloro-pyridin-2-ylcarbamoyl)-methyl]-5-(2-methoxy-ethoxy)-1H-pyrrolo[2,3-c]pyridine-2-carboxylic acid (1-isopropyl-piperidin-4-yl)-amide,  
 1-[(5-Chloro-pyridin-2-ylcarbamoyl)-methyl]-5-(2-hydroxy-ethoxy)-1H-pyrrolo[2,3-c]pyridine-2-carboxylic acid (1-isopropyl-piperidin-4-yl)-amide ,  
 1-(6-Chloro-benzo[b]thiophen-2-ylmethyl)-5-(2-methoxy-ethoxy)-1H-pyrrolo[2,3-c]pyridine-2-carboxylic acid (1-isopropyl-piperidin-4-yl)-amide or  
 1-(6-Chloro-benzo[b]thiophen-2-ylmethyl)-5-(2-hydroxy-ethoxy)-1H-pyrrolo[2,3-c]pyridine-2-carboxylic acid (1-isopropyl-piperidin-4-yl)-amide .

9. A process for the preparation of a compound according to claim 1, which comprises condensing a compound of formula **29** with a compound of the formula  $\text{HR}^{8'}$  to give a compound of formula **30** and converting the compound of the formula **30** into a compound of the formula I,



wherein the residue  $\text{R}^{8'}$  has the donation of  $-\text{N}(\text{R}^1)-\text{R}^2-\text{V}-\text{G}-\text{M}$  as indicated claim 1, but where in  $\text{R}^{8'}$  functional groups can also be present in the form of groups that are subsequently transformed into the final functional groups present in  $-\text{N}(\text{R}^1)-\text{R}^2-\text{V}-\text{G}-\text{M}$ , and where the residue  $\text{R}^{54}$  denotes the group  $-\text{Q}-\text{R}^0$  or can denote a group which is subsequently transformed into the group  $-\text{Q}-\text{R}^0$ , and where the group  $-\text{C}(\text{O})-\text{R}^{53}$  can be a carboxylic acid group or derivatives thereof, and where the groups  $\text{R}^{3a}$  in the formulae **29** and **30** have the corresponding definitions of  $\text{R}^3$  in formula I as defined in claim 1 or functional groups in them can also be present in protected form or in the form of precursor groups.

10. A pharmaceutical composition, comprising at least one compound according to claim 1 and a pharmaceutically acceptable carrier.

11. A method for inhibiting factor Xa in a patient in need thereof, comprising administering to the patient a pharmaceutically effective amount of a compound according to claim 1.
- 5 12. A method for inhibiting factor VIIa in a patient in need thereof, comprising administering to the patient a pharmaceutically effective amount of a compound according to claim 1.
13. A method for influencing blood coagulation in a patient in need thereof, comprising administering to the patient a pharmaceutically effective amount of a compound according to claim 1.
- 10
14. A method for inhibiting influencing blood fibrinolysis in a patient in need thereof, comprising administering to the patient a pharmaceutically effective amount of a compound according to claim 1.
- 15
15. A method for treating abnormal thrombus formation, acute myocardial infarction, cardiovascular disorders, unstable angina, thromboembolism, acute vessel closure associated with thrombolytic therapy or percutaneous transluminal coronary angioplasty (PTCA), transient ischemic attacks, stroke, intermittent claudication, bypass grafting of the coronary or peripheral arteries, vessel luminal narrowing, restenosis post coronary or venous angioplasty, maintenance of vascular access patency in long-term hemodialysis patients, pathologic thrombus formation occurring in the veins of the lower extremities following abdominal, knee or hip surgery, pathologic thrombus formation occurring in the veins of the lower extremities following abdominal, knee and hip surgery, a risk of pulmonary thromboembolism, or
- 20
- 25
- 30
- disseminated systemic intravascular coagulopathy occurring in vascular systems during septic shock, viral infections or cancer, or reducing an inflammatory response, fibrinolysis, or treatment of coronary heart disease, myocardial infarction, angina pectoris, vascular restenosis, for example restenosis following angioplasty like PTCA, adult respiratory distress syndrome, multi-organ failure and disseminated intravascular clotting disorder, deep vein or proximal vein thrombosis, which can occur following surgery, in a patient in need thereof, comprising administering to the patient a pharmaceutically effective amount of a compound according to claim 1.